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ABSTRACT 
Hemangiosarcoma is the neoplastic growth of primitive cells that resemble 
endothelial cells. Dogs with hemangiosarcoma often present on an emergency basis due 
to tumor rupture and intraabdominal bleeding. Treatment involves hemodynamic 
stabilization, surgery to remove the bleeding tumor and chemotherapy to address 
micrometastatic disease, which is presumed to be present at the time of diagnosis. 
Allogeneic blood transfusions are often required in the perioperative period to address 
blood loss. With recent advances in human medicine, the liberal use of allogeneic blood 
products in patients with cancer has been called into question. Intraoperative cell salvage 
offers an alternative method to restore blood volume in dogs with intraabdominal 
bleeding, but the concern for iatrogenic tumor cell dissemination exists. The first 
objective of this study was to determine if the administration of allogeneic blood 
products negatively affects time to disease progression in dogs undergoing surgery for 
hemangiosarcoma. The second objective of this study was to determine the ability of an 
intraoperative cell salvage system with a leukocyte reduction filter to remove 
hemangiosarcoma cells from dog blood ex vivo. 
Retrospective data were collected from two hospitals to include dogs undergoing 
surgery for hemangiosarcoma. Six variables were analyzed to determine predictors of 
time to disease progression. The administration of allogeneic blood products was found 
to be independently associated with shorter time to disease progression. For the second 
objective, cultured hemangiosarcoma cells were added to dog blood to represent the 
blood that may be encountered during surgery to address a bleeding tumor. The solution 
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was processed through the intraoperative cell salvage machine followed by a leukocyte 
reduction filter. PCR, flow cytometry and cytologic examination were used to determine 
the presence of cultured hemangiosarcoma cells at different points in the intraoperative 
cell salvage system processing. The processing removed a majority hemangiosarcoma 
cells from dog blood.  
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NOMENCLATURE 
ABT Allogeneic blood transfusion 
bFBF Basic fibroblastic growth factor 
CT Computed tomography  
DIC Disseminated intravascular coagulopathy 
HSA Hemangiosarcoma 
IOCS Intraoperative cell salvage 
LR Leukoreduction 
LRF Leukocyte reduction filter 
MST Median survival time 
PCV Packed cell volume 
pRBC Packed red blood cells 
RBC Red blood cell 
TRALI Transfusion-related acute lung injury 
TRIM Transfusion-related immune modulation 
VEGF Vascular endothelial growth factor 
WBC White blood cell 
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CHAPTER I 
INTRODUCTION TO HEMANGIOSARCOMA IN DOGS: 
PATHOPHYSIOLOGY TO TREATMENT 
 
Introduction 
Hemangiosarcoma (HSA) is the neoplastic growth of primitive cells that 
resemble endothelial cells. Dogs are the most common species affected with this tumor 
type. Dogs often present on an emergency basis due to tumor rupture and intraabdominal 
bleeding. Treatment involves hemodynamic stabilization, surgery to remove the bleeding 
tumor and chemotherapy to address micrometastatic disease, which is presumed to be 
present at the time of diagnosis. Because this tumor is intimately associated with the 
systemic vasculature, is quick to metastasize, and is associated with a short survival time 
despite treatment, it is considered highly aggressive with a grave long term prognosis.  
Several options exist to stabilize a dog with an acute abdominal hemorrhage. 
Often crystalloid fluids and allogeneic blood products are used in combination. No 
evidence-based guidelines have been published regarding the use of allogeneic blood 
transfusions (ABT) in dogs with HSA. With proper blood typing and cross matching, 
acute transfusion reactions are rare which has led to the belief that ABT are safe for dogs 
with cancer. 1 However, more long-term consequences of allogeneic blood transfusions 
may exist. Recently in human medicine, the clinical effects of transfusion-related 
immunomodulation (TRIM) have been studied. TRIM refers to the changes in the 
immune system following the administration of ABT and may be especially important in 
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cancer patients. TRIM is believed to be the cause of a shorter tumor-free interval and 
survival time for some types of human cancers. 2-4 The following review will discuss the 
known pathophysiology, current treatment options and the potential role of blood 
transfusions in disease progression for dogs with intraabdominal HSA.   
Epidemiology 
HSA occurs more in dogs than in any other species and dogs are the only species 
that frequently develop naturally-occurring HSA.  5, 6 An estimated 50,000 dogs are 
diagnosed with HSA each year in the United States. 6 Middle-age to older dogs are most 
commonly affected but HSA has been reported in a dog as young as 2 years old. 7 Some 
breeds are overrepresented including: German shepherd, boxer, Golden retriever, 
Labrador retriever, flat coated retriever, poodles, and Bernese Mountain dogs but any 
breed can be affected. 7-9 Males may have a higher prevalence than females. 7,10,11  
The two major types of HSA are visceral and non-visceral. Most of the non-
visceral HSAs are cutaneous. The spleen, right atrium and liver are the most common 
visceral locations of the primary tumor. 10,12  Between 25-67% of dogs with splenic HSA 
are estimated to have right atrial involvement at the time of presentation. 13,14 Splenic 
HSA is rapidly metastatic to the liver, lung, omentum, and mesentery. 13 Since it is a 
neoplasm of cells originating in the bone marrow theoretically any tissue with a blood 
supply can be affected, but the most vascular organs are more commonly affected. 15 In 
fact, HSA is the most common metastatic tumor to the brain. 16 Other tissues that are 
commonly affected by primary or metastatic HSA include: lung, kidney, oral cavity, 
muscle, brain, bone, urinary bladder, left ventricle, lymph nodes, aorta, uterus, tongue, 
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digit, adrenal glands, pleura, pancreas, small intestines, diaphragm, retroperitoneum and 
prostate. 7,16,17 The route of metastasis of HSA has not been studied and may be 
hematogenous, via lymphatics and/or though tumor cell seeding from tumor rupture. 
HSA in dogs is analogous to angiosarcoma in humans. In 1974, Prisetler reported 
that dogs are affected with HSA of the liver at up to 100x the rate of humans and that the 
tumors are histologically similar. 18 The distinguishing features of the 
immunohistochemistry of vascular tumors of dogs and humans are comparable. 19 
Human angiosarcoma and dog HSA cells both express the same cell surface markers and 
originate from primitive endothelial cells. 20, 15,21 Identical antibody markers are used in 
both species for early detection of their respective tumor types and similarities are 
present in the genetic abnormalities in human angiosarcoma and dog HSA. 6,22 The 
biologic behavior of human angiosarcoma and dog HSA is so similar that dogs have 
been used as a model species to study angiosarcoma in people. 23 
Pathogenesis and Tumorigenesis  
Since its description in 1955, HSA was thought to arise from mutated mature 
endothelial cells. 24 Using multi-parameter flow cytometry, Lamerato-Kozicki et al. 
found that HSA cells actually originate in the bone marrow as stem cells that stop 
differentiating early in the maturation process. Whether the HSA cancer stem cells arise 
from de-differentiated somatic cells or if they are a product of mutated stem cells is 
unknown.  15  
A specific carcinogen has not been identified as the cause of abdominal HSA in 
dogs although there is an increased risk in dogs that are prenatally exposed to ionizating 
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radiation. 25 Four DNA-damaging agents responsible for an increased risk of hepatic 
HSA in humans have been identified: thorium dioxide (a radioactive intravenous 
contrast for angiography used in 1930-1955), inorganic arsenic from pesticides, vinyl 
chloride monomers from working with PVC pipes and anabolic steroids. 26 These agents 
have not been studied in dogs.  
The tumorigenesis of HSA is thought to be centered on abnormal progression 
through the cell cycle and deregulated angiogenesis. 27 Angiogenesis is the formation of 
new blood vessels from existing vessels and is normally tightly regulated. Angiogenesis 
is required for metastasis and tumors can initiate this process in several ways. HSA cells 
express growth factors that normally regulate the formation of new blood vessels such as 
vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor (bFBF).
21,27 HSA cells express the receptors for VEGF and bFBF as well as the platelet derived 
growth factor receptor. 28,29, 30  VEGF and bFGF work directly on endothelium to 
stimulate proliferation while platelet derived growth factor works through inflammation 
to induce angiogenesis. 31 VEGF has been also found to enhance the crosstalk between 
tumor cells and the immune cells in their microenvironment. 32 Abnormal or 
dysregulated angiogenesis is one of the links between cancer development and 
inflammation. 33 Overexpression of VEGF can transform immortalized mice endothelial 
cells into HSA that eventually express VEGF receptors. 34 In the mouse model of HSA, 
the mouse will not develop HSA if the autocrine endothelial release of VEGF is deleted.
35 This shows that the uncontrolled secretion of VEGF is a requirement for development 
of HSA in the mouse model. Since HSA cells express both the ligands and receptors for 
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the growth factors responsible for angiogenesis, the stimulation for new blood vessel 
growth is under autocrine control. The inherent autonomous angiogenesis associated 
with HSA helps to explain the aggressive biologic behavior of this tumor.  
The gene signatures found to be abnormal in dogs with HSA are those involved 
in inflammation (IL-8, IL-6, IL-1, COX-2), angiogenesis (VEGF-A, VEGF-R3), 
adhesion (FN-1), invasion, coagulation (Fibronectin 1), metabolism, cell cycle, wound 
healing (FN-1), signaling (ADAMS9), cell-cell interactions, hypoxia-inducible genes, 
metastasis (COX-2, FN-1) and the immune response. 6,11,27 These changes in gene 
expression are specific to HSA and are not simply a consequence of malignancy in 
general. The gene expression of cultured tumor cells is different from those tumor cells 
in whole tissue, which suggests interaction between tumor cells and the surrounding 
stroma and inflammatory cells. 6   Mast cells, which have pro-inflammatory angiogenic 
effects, are found in increased numbers in human angiosarcoma but their presence and 
significance has not been studied for HSA in dogs. 36 The relationship between 
inflammation and tumor progression is synergistic and multifactorial. 33  
Clinical Signs and Diagnosis 
Dogs with HSA may present to the veterinarian with mild to moderate non-
specific clinical signs or may present with signs related to a massive intraabdominal 
hemorrhage due to a ruptured tumor. 7 The length of the clinical latency period of HSA 
remains unknown and the diagnosis is usually made late in the course of the disease. 
7,10,12 Owners may report vague changes leading up to presentation such as lethargy, 
weakness, decreased appetite, or distended abdomen. 13,37  Neurologic signs due to 
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metastatic disease may be the only complaint. 13 Although no clinical signs are 
pathognomonic of HSA, one retrospective study of 271 dogs showed that the observance 
of anorexia, collapse and hemoabdomen at presentation was significantly more common 
in dogs with splenic HSA, whereas abdominal pain, vomiting and diarrhea were more 
likely to be seen in dogs with splenic hematomas. 38 The authors postulate that anorexia 
is associated with cancer cachexia and lethargy is associated with abdominal bleeding 
and those two clinical signs are more likely associated with a malignant process. They 
further propose that slow progressive splenomegaly causing displacement of 
gastrointestinal organs and secondary vomiting, diarrhea and pain before splenic rupture 
and hemorrhage is more likely due to a benign lesion. Subsequent to their study, tumor 
size alone has been proven not predictive of the biologic behavior for splenic masses.
39,40
More than 50% of dogs with HSA are presented to the veterinarian for acute 
collapse, which is likely secondary to hemorrhage or arrhythmia. Physical examination 
may reveal a palpable abdominal mass or abdominal distention. The abdominal 
distention may be from a hemoabdomen or from the tumor itself. 41 Some dogs may have 
a palpable fluid wave, supportive of hemoabdomen. In a retrospective study of dogs with 
splenic masses, 83% presented with hemoabdomen. 42 The dog may show signs of 
hypovolemia and/or anemic hypoxia if there is a recent or ongoing hemorrhage (pallor, 
weakness, collapse, delayed capillary refill time, tachycardia, tachypnea and low blood 
pressure if in decompensated hemorrhagic shock).  If the collapse is due to hemorrhage, 
the extravascular blood in the abdomen may spontaneously undergo autotransfusion 
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after an unknown period of time. The severity of clinical signs will depend on the 
duration and rate of abdominal bleeding. 43 If there is cardiac involvement, the dog may 
show signs of cardiac tamponade, right heart failure or cardiogenic shock. The clinical 
picture for HSA can vary from a normal dog with an incidental splenic mass to a 
severely hypovolemic dog in decompensated shock.  
Initial bloodwork can be variable in dogs with HSA. They often have blood loss 
anemia with abnormal red blood cell (RBC) morphology. Several causes for anemia are 
possible in dogs with HSA such as: blood loss, anemia of chronic inflammation, 
splenomegaly, microangiopathic hemolytic anemia from splenic disease, and 
paraneoplastic syndrome especially if the bone marrow is affected. 41 The complete 
blood count and serum biochemistry may have nonspecific changes but a neutrophilic 
leukocytosis, anemia and thrombocytopenia are more common in dogs with HSA 
compared to those with benign splenic disease. 37,44 In most dogs presenting with HSA, 
measures of coagulation parameters are abnormal. 37,45 About 50% of dogs with HSA 
meet the criteria for disseminated intravascular coagulopathy (DIC) on presentation. 10, 45 
Thrombocytopenia is found in 75-97% of dogs with HSA but it is unclear if this is due to 
increased consumption of platelets from hemorrhage, decreased platelet formation if the 
bone marrow is affected, or a combination. 10,37,45 The abnormalities in the vasculature 
supplying the tumor are thought to contribute to the changes in RBCs morphology and 
coagulation parameters in dogs with HSA. 10 Around 55% of dogs with HSA presenting 
with a hemoabdomen will have elevated lactate, a marker of inadequate tissue perfusion. 
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46 Hyperlactatemia can be caused by tissue hypoxia (Type A hyperlactatemia) or the 
neoplasm itself (Type B hyperlactatemia).  
Determining the cause of the clinical presentation prior to performing surgery 
would be advantageous since the prognosis for survival with a splenic mass depends on 
the etiology. The owners are often faced with the decision to proceed with surgical 
treatment in an emergency situation with relatively few facts and no promise for cure or 
survival. For this reason, work has been done to find a way to accurately diagnose HSA 
prior to anesthesia and surgery. Several clinical factors, imaging characteristics and 
biomarkers have been analyzed to solve this problem. 
Retrospective data have been used in attempt to identify dogs with malignant 
neoplasia based on initial clinical assessment. One retrospective study analyzed medical 
records of 71 dogs with splenic masses, anemia and hemoabdomen that required blood 
transfusion and attempted to predict whether the dog was affected by hemangioma or 
HSA.  The investigators determined a cut off value for serum total protein (< 5.8 mg/dL) 
and platelet count (< 90,000 cells/dL) to predict the presence of HSA. These parameters 
may simply be a surrogate measure of hemorrhage and the positive and negative 
predictive values to diagnose HSA were unacceptably low. 47 This study excluded dogs 
with HSA that did not receive a blood transfusion, dogs with severely abnormal 
coagulation parameters and dogs that were euthanized due to other bleeding masses, so 
the study sample may not represent the population of dogs with HSA. One retrospective 
study of 70 dogs presenting with splenic masses showed that the severity of anemia on 
presentation in dogs with hemoabdomen can be predictive of a malignant splenic tumor. 
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The authors determined that as the PCV of the dog decreased by 10%, the odds of the 
presence of malignancy in the spleen increased 3-fold. In this study, the presence of 
abdominal effusion was associated with a 6-fold increase in the odds of a malignant 
mass. 48  Three other retrospective studies showed that a ruptured mass at the time of 
presentation is more likely HSA than a benign process but one prospective study failed 
to agree. 47,49-51 In one retrospective study of dogs presenting with non-traumatic 
hemoabdomen, those with anemia, nucleated RBC or splenic rupture were significantly 
more likely to be affected by a splenic neoplasm, HSA being the most common. 51 
Despite the reported associations, no clinical presentation is accurately predictive for 
HSA. 
The diagnosis of a hemoabdomen is based on collecting free abdominal fluid and 
determining that the fluid has a packed cell volume (PCV) over 10%. This fluid will not 
clot in a syringe because the platelets are consumed in the clot at the site of hemorrhage. 
41 Non-traumatic hemoabdomen can be caused by several different conditions including 
coagulopathy, ruptured mass (benign or malignant), hepatobiliary disease, gastric 
dilatation volvulus, liver lobe torsion, splenic torsion and caval syndrome from 
heartworm disease. 37,52  Unfortunately, less than 25% of hemoabdomen fluid samples 
will contain detectable neoplastic cells using fluid cytology and false positives are 
possible if a reactive mesothelial cell is included in the sample, so attempting diagnosis 
of HSA from this fluid is not recommended. 41 Although sampling of a mass is 
recommended pre-operatively for many other types of tumors, fine needle aspirates and 
other biopsy techniques are often unrewarding and carry a significant risk of hemorrhage 
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in dogs with splenic HSA. 41 Additionally, seeding tumor cells into the abdomen during 
FNA is possible, although seeding is unlikely to change the clinical course of the disease 
on a large scale. 39 No preoperative test is accurate in predicting if a dog’s hemoabdomen 
is caused by HSA or caused by a different process.    
If HSA is suspected, imaging is recommended to attempt to determine the cause 
of bleeding, to look for metastatic disease and to determine if general anesthesia and 
surgery are indicated for the dog. Abdominal radiographs may be difficult to interpret 
with free abdominal fluid or a mass causing obscuring of serosal detail. Thoracic 
radiographs are obtained to look for metastatic disease and to help determine anesthetic 
candidacy. In dogs with HSA, radiographs are 78% sensitive and 90% specific for 
detecting metastatic disease and have a 92% positive predictive value and 74% negative 
predictive value when 3 orthogonal views are interpreted. 14  Abdominal ultrasound has 
superior image quality with the presence of abdominal fluid. The ultrasonographic 
features of splenic and liver HSA have been described but this test cannot differentiate 
between other lesions such as hematoma, hemangioma and other metastatic tumors. 53 
Computed tomography (CT) provides more abdominal and thoracic detail compared to 
radiographs but requires sedation or anesthesia. Objective parameters obtained from 
contrast enhanced CT can be used to help determine if a splenic mass is benign or 
malignant. The presence of hepatic nodules found on CT is associated with a greater risk 
of splenic malignancy in all dogs with focal splenic masses. 40 Magnetic resonance 
imaging (MRI) can determine if a focal splenic lesion is benign or malignant with the 
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specificity of 90% and sensitivity of 100%. 54 MRI is not used widely because of the 
increased time and cost required to obtain this information.   
Blood-based biomarkers have been investigated for their ability to predict the 
presence of HSA. Based on the pathogenesis of HSA, it is not surprising that plasma 
VEGF and urine bFGF are elevated in dogs with HSA compared to control dogs. 31 The 
limitations of measuring these biomarkers include the lack of normal reference ranges, 
low specificity, and the lack of correlation with disease stage or treatment outcome. 
Serum alpha-1 acid glycoprotein, a marker of inflammation that suppresses immune 
function, is elevated in the serum of dogs with HSA but the clinical utility of this 
measurement has not been further investigated. 55  Thymidine kinase, a biomarker for 
cellular proliferation, is significantly higher in serum of dogs with HSA compared to 
normal dogs; however, this marker was unable to distinguish dogs with HSA from dogs 
with benign splenic changes in a small study. 56 A clinical trial is being conducted to 
determine if this biomarker can be used for the early diagnosis of HSA in dogs. 57 The 
serum levels of the lipocalin region of collagen XXVII α 1 were also found to be 
elevated in dogs with metastatic HSA when compared to dogs with localized HSA, 
tumors other than HSA, and control dogs. Furthermore, serum levels of this biomarker 
correlate with disease remission and recurrence. 58 Clinical validation of this blood-based 
biomarker has not been published but may prove to be valuable in the future. 
Cardiac Troponin I, a marker of myocardial damage, is elevated in the plasma of 
dogs with cardiac HSA compared to dogs with non-cardiac HSA, dogs with other 
tumors, and dogs with pericardial effusion due to other causes. This test may be used to 
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determine if a dog with pericardial effusion is neoplasia-induced and to determine the 
presence of cardiac involvement in a dog with suspected visceral HSA. 59 Multi-
parameter flow cytometry of peripheral blood has been successful at identifying 
circulating HSA cells in affected dogs. Flow cytometry allowed for distinguishing dogs 
with HSA from normal dogs and from dogs with benign splenic disease. Furthermore, 
the number of detectable circulating HSA cells decreased when the tumor was surgically 
removed. Flow cytometry shows promise to detect HSA early in the disease process, 
detect HSA cells in abdominal effusions, and to monitor for disease recurrence. 15  
In summary, clinical factors are inaccurate at predicting the presence of HSA 
although some associations have been described. Advanced imaging modalities can be 
used to predict if a splenic mass is benign or malignant but the tumor origin cannot be 
determined. Biomarkers and flow cytometry are not yet validated but have promise to 
diagnose HSA before surgery and monitor response to treatment in the future. 
Histopathology of a surgically excised biopsy is the gold standard for the diagnosis of 
HSA. HSAs have a variable amount of hemorrhage within the tumor and can form 
secondary hematomas, which if examined by a pathologist may lead to the wrong 
diagnosis with a very different prognosis. 60 The distinction is important and can be 
challenging.  
Clinical Staging 
 Despite the efforts to find a reliable method of preoperative HSA diagnosis, the 
diagnosis is not typically made until histopathology results are available several days 
after surgery. For this reason, staging the dog for metastatic disease is often 
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recommended as part of the pre-surgical work up in order to provide as much 
information to the owner as possible.  
Clinical staging for HSA uses the tumor, node, metastasis (TNM) system and 
was first described by Brown in 1985. 7 Stage I indicates a tumor confined to the spleen, 
stage II indicates a ruptured splenic tumor or local lymph node metastasis and stage III 
indicates a tumor invading other tissues or distant metastasis. A majority of dogs present 
with stage III disease. 7,10,61 Several studies of dogs with HSA did not find a difference in 
survival time between the dogs in each of the 3 stages. 7,12,39,51 However, the dogs 
received a variety of treatments that have been shown to affect survival times and this 
variable was not taken into account when comparing survival.  Others have found that 
the presence of metastasis at the time of diagnosis of HSA has a significant influence on 
survival. By examining pathologic specimens of splenic HSA, one report retrospectively 
determined the median survival time (MST) for dogs with and without metastatic disease 
to be 0 and 97 days respectively. 60 Another retrospective report of dogs with HSA 
treated with surgery alone showed a strong relationship between the disease stage and 
survival time. Groups of dogs with stage I, II and III HSA showed a MST of 
approximately 5 months, 2 months and less than 1 month respectively. 62  Since surgery 
for removal of the primary tumor in a dog with metastatic lesions would likely allow for 
only a short survival time, clinical staging might help to guide treatment decisions. 62,63   
Pre-Surgical Stabilization 
Pre-surgical stabilization is aimed at resolving the dog’s cardiac arrhythmias and 
hypovolemia if present. The degree of stabilization required is determined by the status 
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of the dog. Around 44% of dogs presenting with splenic masses and 70% of dogs 
presenting with a hemoabdomen develop arrhythmias. 50 Ventricular arrhythmias are 
best detected with continuous electrocardiography (ECG) compared to intermittent ECG 
readings. The indications for treatment of ventricular arrhythmias are: sustained 
ventricular tachycardia, superimposition of an ectopic beat on the T wave of the 
preceding beat (R on T), multiform beats, and if the clinical status of the dog is affected 
by the arrhythmias. 64 Dogs may also develop sinus tachycardia, likely as a symptom of 
compensation for hypovolemia in response to increasing sympathetic tone in order to 
preserve cardiac output. Arrhythmias may also be caused by myocardial reperfusion 
injury or secondary to splenic disease itself as the spleen has direct effects on left 
ventricular contractility. 50 The consequences of arrhythmias vary in dogs with splenic 
disease, from an incidental finding to life-threatening.  
Transfusion Trigger 
A transfusion trigger is the point when the available clinical data provokes the 
clinician to prescribe blood products. There are no research-based recommendations for 
the safe and effective use of blood products in dogs with HSA. 65 Anecdotal transfusion 
triggers include a PCV of 20 to 25% or lower in dogs with hemoabdomen or a PCV 
lower than 12%. 41, 66 A PCV lower than 12% is recommended as an absolute indication 
for blood component therapy in dogs since a lower PCV is associated with an increased 
risk of multiple organ failure in human patients. 67 The indication for administering 
packed red blood cells (pRBC) is to treat anemic hypoxia. 68, 65 Precise diagnosis of this 
condition is challenging in a clinical setting. The clinical signs caused by anemic 
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hypoxia are non-specific and depend on the duration and severity of anemia. The 
physiologic responses to anemic hypoxia are aimed toward improving oxygen delivery 
to specific tissues and include: increased sympathetic tone causing increased cardiac 
output and shunting of blood from non-essential organ systems, decreased left 
ventricular afterload due to decreased blood viscosity, right-shift in the oxyhemoglobin 
dissociation curve and recruitment of capillaries in essential organ systems. 69Anemic 
hypoxia cannot be diagnosed using PCV alone. 65 Rather than relying on a PCV cut-off 
value, accurate methods that measure global tissue oxygenation such as arterial lactate, 
oxygen extraction ratio, gastric pH and cellular oxygen consumption should be used to 
study research-based transfusion triggers. 67 
In 1943, Adams declared a transfusion trigger for human surgical patients to be a 
PCV of 24-30%. 70 Since then, the use of this relatively liberal, arbitrary range has been 
questioned in both human and veterinary medicine. The famous CRIT Study, a 
prospective study with almost 5000 ICU patients, showed that administration of ABT 
was an independent predictor of increased morbidity and mortality during the hospital 
stay. 71 Since then, another large prospective study had similar findings. 72 In one 
retrospective study of over 10,000 severely anemic human patients undergoing non-
cardiac surgery, the administration of 1 or 2 units of allogeneic blood was independently 
associated with a 40-90% increase in 30 day morbidity and a 29% increase in mortality. 
Morbidities included pulmonary, septic, wound, and thromboembolic complications. 73 
Although it is possible that the complications were associated with intraoperative 
bleeding, the investigators included only patients with severe preoperative anemia, only 
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those that received 1-2 units of blood and those undergoing non-emergency surgeries in 
an effort to eliminate patients with severe intraoperative blood loss. Another prospective 
study which included general surgery patients who received 1-2 units of ABT for any 
reason showed that there was a dose-dependent increase in 30-day morbidity and 
mortality associated with ABT administration. 74 A prospective study of human patients 
that were treated with splenectomy for various reasons found that the administration of 
ABT during hospitalization was the only independent risk factor for morbidity. 75 The 
results from a systematic review of human critical care studies showed that in 42 out of 
45 studies, the risks of ABT outweighed the benefits. 76 
The association between ABT and morbidity has been demonstrated in dogs. A 
retrospective study of over 200 dogs that received ABT showed that accounting for 
disease severity, a high pre-transfusion PCV and high dose (in mL/kg) of pRBC 
administered were both risk factors for dogs not surviving hospitalization. 77  This study 
suggests that even in the presence of anemia, the use of ABT may be detrimental to 
patients in whom a transfusion is not indicated.  
The ideal transfusion trigger would ensure that animals with life-threatening 
anemic hypoxia were provided with hemoglobin support but animals with tolerable 
levels of anemia are not given ABT, therefore avoiding the associated risks. The 
tolerance to anemia in a given animal depends on many factors such as the cause of 
anemia and the rate of development of anemia. 65 For several subpopulations of high-
risk, critically ill human patients, Spahn showed that a restrictive transfusion trigger of 
PCV < 21% is associated with less morbidity and mortality in the hospital compared to a 
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more liberal transfusion trigger. 78 In healthy human patients, acute normovolemic 
reduction of PCV to 15% had no effects on the measures of tissue oxygenation. 79 These 
studies show that hypovolemia and anemia are relatively well tolerated in humans and 
must be severe to result in morbidity, mortality and poor tissue oxygenation. However, 
these findings may not be applicable to dogs. 
One experimental dog study provides valuable information for establishing a 
research-based transfusion trigger. In healthy dogs, tissue oxygen delivery is normal 
until 50% of the blood volume is lost via hemorrhage. Tissue oxygen delivery is normal 
until the PCV falls below 8% in normovolemic dogs. 80 These findings demonstrate that, 
as in humans, anemia and hypovolemia must be severe to impair tissue oxygen delivery 
in healthy dogs. However, the findings in these healthy dogs may not be directly 
translated to dogs with HSA. Therefore, the transfusion trigger may be different in dogs 
with a hemoabdomen due to a bleeding splenic mass.  
Because of the lack of research-based transfusion triggers, the over-use of ABT 
during pre-surgical stabilization for dogs with HSA cannot be accurately defined at this 
time. In one retrospective study of 83 dogs with hemoabdomens, all dogs were given an 
ABT but the median PCV on presentation was 29% with a range of 9% to 71% and the 
median heart rate on presentation was 146 beats per minute with a range of 80 to 225 
beats per minute. 46 In another retrospective study of dogs with anemia and splenic 
masses, 18 dogs without hemoabdomens received 22 ABT. 47 The mean PCV of all 
transfused dogs in this study was 27% with a range of 13% to 47%.  This wide range of 
transfusion triggers demonstrates the variety of dogs that receive ABT, likely due to a 
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lack of guidelines. Mirroring the confusion in the veterinary literature, one study of 
human clinicians and residents showed that ABT are prescribed by surgeons and 
anesthesiologist without their full understanding of the indications, risks and benefits of 
transfusions. 81 Since the short-term side effects are rare and ABT administration is 
likely to improve bloodwork values, ABT may be overprescribed in human and 
veterinary medicine. Until recently, the negative long-term side effects of ABT have 
been overlooked.  
Transfusion Related Immunomodulation  
Transfusion related immunomodulation, or TRIM, is the poorly understood 
immunologic consequence of ABT that may have long-term clinical effects. Clinical 
consequences attributed to TRIM in humans include: improved organ transplant 
survival, enhanced tumor progression, increased postoperative infection risk, 
improvement of symptoms of autoimmune disease, and transfusion-related acute lung 
injury (TRALI).  82 These effects can partially be explained by the immunomodulatory 
and/or pro-inflammatory changes seen after administration of ABT but the full 
mechanism remains undiscovered. 83 
The immunosuppressive effects of ABTs were first noticed in 1973 when Opelz 
reported that fewer human renal transplant recipients experienced transplant rejection 
after receiving ABT, in a dose-dependent manner. 84 The same finding was reported in 
laboratory dogs undergoing renal transplant. 85 As cyclosporine became more popular 
and offered the same effects as an ABT, the use of ABT to reduce transplant-rejection in 
humans was discontinued. 82, 86  
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Ghant suggested that in cancer patients, the immunomodulatory effects of ABT 
may have long-term consequences in these already immunocompromised patients. He 
postulated that since tumor cell antigens were not different than histocompatibility 
antigens, ABT may cause a non-selective immunosuppression that can allow for 
malignant tumor cells to survive. 87 Two years later, Horimi showed that ABT enhanced 
implanted tumor growth in mice. 88 The tumor-promoting effect of ABT administration 
was seen across species and has become more apparent in humans since Gantt’s findings 
were published. In one prospective study of over 300 human colorectal cancer patients, 
perioperative ABT administration and tumor stage were the only two variables to 
independently negatively affect disease free survival. 2 A randomized controlled trail of 
patients with potentially curable resectable colorectal tumors compared disease-free 
survival rates between patients randomized to receive ABT or autologous pre-donated 
blood if needed during surgery. Again, results showed ABT and tumor stage were the 
only two variables to independently negatively affect disease-free survival. 89 A recent 
meta-analysis of 36 studies showed a dose-dependent negative effect of ABT on patients 
with curative-intent colorectal cancer surgeries. 90 These studies highlight the importance 
of considering the immunomodulatory effects of ABT, especially in cancer patients.  
Although a causal relationship between ABT and immunomodulation leading to 
tumor progression in the recipient is difficult to prove, experimental research has been 
performed to find the mechanisms of action. The cellular and biochemical changes 
detected following ABT administration in cancer patients was studied by Guo et al. 
Patients with malignant gastrointestinal tumors were grouped into patients who received 
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perioperative ABT and patients who received autologous blood. Several markers of 
immune dysfunction were identified in patients receiving ABT. The ABT group had 
decreased natural killer (NK) cell activity. 1 NK cells play an important role in the 
immune-system’s tumor cell recognition and killing mechanisms. NK cells work to 
prevent metastasis and emboli of tumor cells. 91 In addition to lower NK cell activity, 
plasma IL-10 levels were increased in the ABT group, which leads to a shift of T-cell 
phenotype from T-helper 1 to T-helper 2 (Th2). A T-helper cell imbalance was present 
in people receiving ABT for at least 7 days post-surgery, with more Th-2 cells found 
after ABT administration. 1 The cytokines produced by Th2 cells depress cytotoxic T-
cell and macrophage activation, which are important anti-tumor effects of the innate 
immune system. 82 Further, plasma IL-2 was significantly decreased in the ABT group. 
This cytokine enhances T-cell, B-cell and NK cell function. Additionally, IL-2 is 
involved in activating macrophages to kill tumor cells. 33  Postoperative immunoglobulin 
was also significantly decreased in the ABT group, indicating an impaired humoral 
immune response. In light of these findings, the study author suggests that 
autotransfusion be employed in cancer patients whenever possible. 92 A different 
investigator described a dose dependent increase in production of prostaglandin E 2 
(PGE2) and thromboxane by macrophages following ABT. 93 PGE2 is an 
immunosuppressive prostanoid that downregulates antigen presentation and IL-2 
production. 86 The role of PGE2 in TRIM was further supported when Perez et al. 
demonstrated that ABT-induced immunosuppression was enhanced when linolenic acid, 
a precursor of PGE2, is abundant in the diet of rats. 94 The role of dietary modulation of 
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the immune system in ABT recipients was dramatic in the rat model, but has not been 
further explored. The mechanism of TRIM involves inhibition of the innate and humoral 
immune system which has been demonstrated in people with cancer. These subclinical 
changes to immune system function may contribute to the negative effect of ABT 
administration in some patient populations. 
In addition to the changes seen in the immune system, the effects of TRIM may 
also be due to systemic inflammation. ABT enhances the inflammatory insult of surgery 
and anesthesia via directly inducing the release of inflammatory mediators in human 
patients. 95 An acute inflammatory response to stored blood administration has been 
demonstrated in two veterinary studies. 96,97 Inflammation promotes tumor growth by 
contributing to genetic instability, recruiting factors for angiogenesis, increasing cell-cell 
interactions, increasing growth factor release, and increasing stromal remodeling to 
allow for tumor spread. 33,98,99  Systemic inflammation enhances micrometastatic lesion 
expansion via multiple mechanisms. 100 Tumor cells are able to use the adhesion 
molecules that they induce and the white blood cell (WBC)-derived cytokines to 
colonize distant sites. 33  Tumor-induced inflammation is one of the hallmarks for cancer. 
101 The synergy between cancer and inflammation paired with the inflammatory changes 
secondary to ABT administration may help to explain the negative effects demonstrated 
with ABT administration in cancer patients.  
TRALI, or transfusion-related acute lung injury, is the severe diffuse lung 
pathology that occurs in a small proportion of human patients within six hours of ABT 
administration. 102 The pathophysiology behind TRALI is poorly understood but may be 
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a significant link between inflammation and tumor progression for cancer patients 
receiving ABT. The final result of TRALI is increased capillary permeability and 
neutrophilic infiltration into the lungs. 65 The capillary integrity in the lungs is an 
important barrier to extravasation of metastatic cells in this highly perfused organ. 
Extravasation and colonization of metastatic cells may be achieved easier in patients 
with compromised capillary integrity.  The incidence of TRALI in dogs receiving blood 
transfusions perioperatively for HSA is unknown but in a retrospective study of dogs 
with splenic masses, 2 of 518 (0.004%) dogs undergoing a transfusion experienced 
TRALI and 2 of the 41 (5%) dogs that did not survive to discharge died of TRALI. 42 
Even in the absence of overt TRALI, the administration of stored autologous blood is 
associated with pulmonary vascular leakage in healthy dogs. Dogs given blood that had 
been stored for 21 days showed significant microscopic and macroscopic evidence of 
pulmonary edema and perivascular hemorrhage compared to dogs given fresh 
autologous blood. 103 Because of the propensity for HSA to metastasize to the lungs, we 
suspect that ABT-induced pulmonary vascular changes may be especially relevant to 
dogs undergoing treatment for HSA. 
Soluble mediators that are released during blood storage may account for some 
of the inflammatory and tumor-promoting changes seen in dogs administered banked 
blood.  In stored human blood, WBCs release inflammatory mediators such as histamine, 
VEGF, myeloperoxidase, and plasminogen activator inhibitor-1, which accumulate over 
time. 104  Stored dog blood accumulates mediators such as VEGF, IL-8 and 
microparticles, all which have been shown to enhance HSA growth and survival. 21,31,105-
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109 Microparticles are cell fragments that have been recently recognized for their 
involvement with inflammation, tumor progression, angiogenesis and metastasis. 110  The 
clinical consequences of these mediators are unknown but when administered to a blood 
recipient, can help explain the acute inflammatory response which may be especially 
important in dogs with HSA. 
 Leukoreduction (LR) is the removal of WBC using a filter. The use of LR is 
underexplored in veterinary medicine.   VEGF, WBC and platelets are removed from 
dog blood with pre-storage LR. 105, 111  Also, the viability of dog RBCs are normal after 
LR processing. 112 One study evaluated the consequences of autologous blood 
transfusions with or without prestorage-LR. When blood from healthy dogs was stored 
for 21 days and returned back to the donor, total WBC count, mature neutrophils, C-
reactive protein and fibrinogen (markers of acute inflammation) were all elevated despite 
the absence of clinical signs of transfusion reactions. These biochemical changes did not 
occur in dogs given autologous blood that underwent LR before storage. 96  Therefore, 
the administration of stored WBC results in an acute inflammatory response in the 
recipient, even with autologous blood transfusions. LR may reduce some of the aspects 
of the transfusion-induced inflammatory response during the administration of ABT, but 
the absence of WBC does not completely negate the effects of TRIM. 97,113, 82  
Because negative clinical effects are demonstrated following ABT administration 
in cancer patients, determining if a causal relationship exists between ABT and tumor 
recurrence is of importance. Administration of ABT may be a marker for more severely 
affected patients, which would affect the results of retrospective and observational 
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studies. The cause of cancer recurrence is multifactorial and difficult to understand using 
retrospective or observational studies. 114 Several potentially confounding factors that 
may affect tumor recurrence exist in the perioperative setting. Prospective, double-
blinded randomized control trials, taking into account all known confounders, are needed 
to determine if the relationship between ABT and cancer recurrence is causal. Despite 
the limitations of the currently available literature, the possible negative consequences of 
ABT administration should be considered. 
Several disadvantages are associated with the administration of ABT in dogs. 
First, either an established blood bank or on-site blood donors are required.  Second, 
blood typing and cross-matching are recommended in some dogs to reduce the risk of a 
clinically significant transfusion reaction. Third, stored blood has decreased oxygen 
carrying capacity and accumulated inflammatory mediators compared to fresh blood. 76, 
115Additionally, albeit uncommon and usually mild, the incidence of an immediate 
transfusion-related complications is 37% in dogs. 77 Furthermore, the long term 
consequences of ABT are poorly understood. The question remains whether autologous 
blood administration can ameliorate the disadvantages encountered with ABT 
administration. The cumulative effects of inflammatory insults (surgery, ABT) and 
immunosuppression (surgery, anesthesia and TRIM) may affect short and long-term 
outcome in dogs with HSA. 
Intraoperative Cell Salvage with Leukocyte Reduction Filtration 
 Alternatives to ABT have been explored to address anemic hypoxia. Some 
alternatives include xenotransfusion with bovine hemoglobin-based oxygen carrying 
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products and acute normovolemic hemodilution, but neither is currently used clinically 
in dogs. 65,116 An alternative to ABT is intraoperative cell salvage (IOCS) for 
autotransfusion. IOCS was first described by Highmore in 1874 as a life-saving measure 
for women who lost blood during childbirth. 117 By 1968, two commercially available 
IOCS machines were developed for use in trauma patients. 118  
IOCS involves recovering and washing the blood shed during surgery, 
concentrating the RBC, filtering the WBC and platelets and returning the pRBC to the 
patient. 119, 120 In 1991, IOCS was first described in dogs with non-neoplastic causes of 
bleeding as a case series.  A combination of IOCS and ABT was used to address 
complications from a castration, a portosystemic shunt ligation and heart worm disease.  
No short term complications were noted. 121,122 
The Haemonetics Cell Saver System (Fresenius Kabi AG, Ban Homburg, 
Germany) is one of the commercially available IOCS machines.  The system allows for 
aspiration of blood from the surgical field using a double lumen suction tip. Dilute 
heparin is exposed to the salvaged blood at the distal end of the suction tip to prevent 
clot formation. The blood then passes through a cardiotomy reservoir with a 140µm 
filter to remove gross debris. Then, the blood is pumped into the disposable bowl housed 
in the centrifuge. In the centrifuge, the RBC settle to the bottom while the plasma, a 
portion of the WBC, platelets, free hemoglobin, cell debris, medications, activated 
clotting factors and wash fluid are removed from the top. 120,122 When the cells in the 
bowl reach a PCV of about 60%, they are washed with saline and pumped into a blood 
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bag. The pRBC are then passed through a leukocyte reduction filter (LRF) and given to 
the patient, during surgery or within 18 hours of blood collection. 120  
IOCS only saves healthy RBC. 123 Using the Cell Saver System, Ray et al. 
showed that RBC salvaged during spinal surgery have a normal lifespan of 30 days. 123 
Compared to ABT, salvaged blood has been shown to have increased longevity, 
increased 2,3-disphosphoglycerate levels, increased adenosine triphosphate levels and 
improved conformability which is important for capillary circulation.  For these reasons, 
tissue oxygen delivery is expected to be greater for RBC processed with IOCS when 
compared to ABT. 119  
There is legitimate concern for iatrogenic dissemination of tumor cells shed 
during oncologic surgery using IOCS. In 1984, Homann showed that carcinoma cells 
can survive an autotransfusion system and induce tumor formation in athymic mice. 124 
The manipulation of a tumor in surgery increases the number of circulating tumor cells 
and the number of tumor cells shed during surgery. 125 For these reasons, it is prudent to 
attempt to remove tumor cells from the blood encountered during surgery before 
returning the blood to the patient. 
LRFs have a role in IOCS for autologous transfusion. 126 In experimental settings, 
LRFs have been shown to remove a variety of tumor cells from different types of fluid 
media. The tumor cell types that have been studied include: prostatic carcinoma, 
hepatocellular carcinoma, lung carcinoma, breast carcinoma, colon carcinoma, 
pancreatic carcinoma, gastric carcinoma, lymphoma, and leukemia. LRFs are capable of 
removing both cultured tumor cells and primary tumor cells harvested from human 
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cancer patients during tumor resection. 126-135  Catling et al. found tumor cells in 68% of 
blood samples following IOCS processing but no tumor cells were found after passage 
through the LRF. 136 Laing et al. found that during liver transplantation for 
hepatocellular carcinoma, about 63% of patients had tumor cells in the blood shed 
during surgery and that the LRF removed all of these cells except for in one case, when 
the tumor ruptured in surgery.  The researchers theorized that the LRF has a limit to how 
many cells it filters. 137 The role of LRF for removing tumor cells in veterinary medicine 
has yet to be explored. 
Although the direct comparison of ABT vs. autologous blood transfusion is 
difficult, several studies have found improved to no change in survival time in cancer 
patients receiving autologous blood compared to ABT. 138-143 Long term follow up has 
been studied in human patients with hepatocellular carcinoma. Groups receiving either 
autologous blood salvaged during surgery or ABT were compared. The group that 
received autologous blood had a significantly longer tumor-free interval and a 
significantly higher 10 year survival rate. 144 This study offers the longest follow up of 
all IOCS studies that compared survival after surgery in cancer patients. At this point, 
few contraindications exist for use of IOCS in human medicine. 145 Since the LRF is 
capable of removing tumor cells shed during surgery and no negative effect on cancer 
recurrence with IOCS use has been found, IOCS with LRF has been deemed safe for use 
in human oncologic surgeries. 146 
The complication rate for IOCS in humans is 0.027%, significantly less than the 
reported complication rate of 0.14% for allogeneic blood product administration. 147 
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Reported complications of ABT include: febrile nonhemolytic allergic reactions, and 
acute hemolytic transfusion reaction secondary to a hospital error. 147 With the use of 
IOCS, the concern for a coagulopathy exists since the platelets, clotting factors and 
fibrinogen may be removed with processing.  However, in humans, up to 3 L of blood 
can be autotransfused using IOCS with no clinically relevant changes in coagulation. 148 
The limited reports of IOCS use in dogs shows that ionized calcium and magnesium may 
become depleted with autotransfusion but no other electrolyte or acid/base abnormalities 
were found. 149  
If IOCS were to be studied in dogs with HSA, the need to filter autologous blood 
before returning it to the dog is in question. First, it has not been proven that tumor cells 
are shed and therefore collected during surgery in dogs. Although not proven in dogs, 
tumor cells have been found in the operating field for several tumor types in humans. 
125,150,151, 137  The presence of tumor cells shed during surgery is important to determine 
because circulating tumor cells have distinct characteristics and behavior compared to 
tumor cells shed from the primary tumor in surgery. 152 HSA cells have been found in the 
free abdominal fluid in dogs but the concentration and viability of these cells is 
unknown. 15 Second, it is unknown if all tumor cell types are able to survive IOCS 
processing, although cultured and primary carcinoma cells prove to be tumorigenic after 
processing.  152, 153 Third, if tumor cells survive IOCS processing and are returned to the 
patient, it is unknown if those cells are capable of forming new tumors or have any other 
clinical consequences. Metastasis is a very inefficient and complicated process; an 
estimated 0.1% of disseminated tumor cells are capable of forming a metastatic lesion. 
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154 Wang et al. estimates that in dogs with HSA, at least 1% of circulating nucleated 
cells are HSA cells, but their ability to form metastatic lesions is unknown. 155 Fourth, 
even if the cells survive IOCS and exhibit tumorigenicity, it is unknown if this affects 
quality of life and survival time in dogs with a life-limiting disease such as HSA.  
 No evidence-based guidelines are available to determine when ABT is beneficial 
to dogs with hemoabdomen. The potential consequences of anemic hypoxia must be 
fully understood by the clinician and weighed against the benefit of ABT. A restrictive 
transfusion trigger for certain human patients has proven beneficial. TRIM should be 
considered as an important drawback to ABT, especially in recipients with cancer. 
TRIM may be avoided by using IOCS with LRF, but further studies are needed in 
veterinary medicine to deem this alternative method safe. In the meantime, current 
recommendations are to use surrogate measures of tissue oxygenation, such as serum 
lactate, base deficit and mixed/central venous oxygen saturation and clinical signs to 
help guide decision making for ABT use in dogs. 65  
Treatment and Prognosis  
The initial treatment for visceral HSA is surgical removal of the primary tumor. 
The prognosis for surviving splenectomy for splenic masses is good. One retrospective 
study of 539 dogs showed that a majority (92.4%) of dogs survived surgery. However, 
dogs found to have HSA were more likely to die in the hospital compared to dogs with 
any other types of splenic masses, both malignant and benign (OR, 2.13; 95% CI, 1.04 to 
4.39). The presence of hemoabdomen was not related to survival from the hospital in 
dogs undergoing splenectomy.	42 In a study of 83 dogs with hemoabdomen, factors 
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associated with death before leaving the hospital included: tachycardia, bicavitary 
effusion, severe respiratory disease, and the requirement of massive blood product 
transfusions (volume of blood products given in excess of the dog’s blood volume).	46 
Reported short-term complications for splenectomy include uncontrollable hemorrhage 
from metastatic lesions, DIC, portal system thrombosis, pulmonary thromboemboli, and 
cardiac tamponade due to right atrial masses.	42  
Performing surgery alone without subsequent chemotherapy administration has 
been questioned as a treatment option due to the biological behavior of this tumor.  The 
MST of dogs with splenic HSA treated with surgery alone is 1.6 months. 62 Still, surgery 
seems to improve quality of life of the dog in the short term. 39,51,156 Out of 43 surgeries 
performed for dogs with HSA, only 41% were successful at removing all macroscopic 
disease. 157 Knowingly leaving tumor cells behind in surgery defines palliative intent, 
rather than curative intent. In other words, the surgery addresses the life-threatening 
hemorrhage but metastatic disease remains.  
Doxorubicin is the most commonly studied chemotherapy drug and if used after 
surgery has the potential to extend survival time to 4-8 months. 60 The administration of 
doxorubicin is typically initiated 10-14 days after surgery, once the histopathologic 
diagnosis has been made. 158 Intraperitoneal nonpegylated liposome encapsulated 
chemotherapy has been evaluated as a treatment option for intraperitoneal metastasis. 
Fewer peritoneal metastatic lesions were detected in dogs treated with intraperitoneal 
chemotherapy compared to those dogs treated with doxorubicin intravenously (33-81% 
respectively). Unfortunately, the study was unable to determine if intraperitoneal 
 31 
 
chemotherapy affected survival time. 61  Chemotherapy without surgical treatment has 
been evaluated and has a low response rate (47%) and high rate of serious toxicities 
(21%). 159 Inhaled chemotherapy allowed for shrinkage of pulmonary metastatic lesions 
in one of three dogs studied with HSA. No toxic side-effects were noted in this study and 
this mode of chemotherapy delivery needs more investigation. 160  
Low-dose metronomic chemotherapy is an alternative to traditional 
chemotherapy with a low profile of side-effects. The low, continuous systemic drug 
levels are thought to suppress angiogenesis and therefore slow tumor growth. In a small 
study, a treatment group of nine dogs with stage II HSA were treated with a daily dosing 
chemotherapy protocol which included piroxicam, a non-steroidal anti-inflammatory 
drug, and two other conventional anti-tumor medications.  When compared to historical 
controls, dogs treated with the metronomic chemotherapy protocol showed improved 
MST to six months. However, no difference was found in the time to disease recurrence 
between groups. This metronomic chemotherapy protocol was well-tolerated as no 
toxicity was reported. 161 More studies need to be conducted to determine its efficacy. 
The relative success of anti-inflammatory drugs in HSA management supports the theory 
that inflammation is important in the pathogenesis. 6 The prognosis following surgery 
and chemotherapy is nonetheless grave, with a reported 7-11% 1 year survival rate. 62 
Since angiogenesis is central in the pathogenesis of HSA, anti-angiogenic 
treatments have been investigated as an adjunct treatment. Tumors can make angiogenic 
factors themselves, recruit normal cells to make them, induce angiogenic factor 
activation from their surrounding stroma and suppress antiangiogenic processes both 
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locally and for the metastatic cells. 162 Interleukin-12 (IL-12) is a cytokine with 
antiangiogenic properties that also has the potential to stimulate anti-tumor natural killer 
cells. Mice with experimentally induced dog HSA treated with IL-12 injections showed 
inhibition of angiogenesis and tumor growth. 163 While this treatment modality shows 
promise, care must be taken when interpreting xenograft studies.  
Other medications have been studied for their anti-tumor effects such as 
minocycline and Yunnan Baiyao. Matrix metalloproteinases are catabolic proteins 
recruited by tumors from the surrounding stroma to allow for tissue invasion, a required 
step for metastasis. Human and dog clinical trials are underway to determine if inhibiting 
these enzymes allows for a longer time to tumor metastasis. 158 Minocycline has 
antiangiogenic and matrix metalloproteinase inhibitor activity but when looked at in a 
small group of 18 dogs with HSA, the addition of minocycline to the chemotherapy 
protocol did not significantly improve survival time despite allowing for cure in mice 
with experimentally induced fibrosarcoma and lung tumors. 12,164  As with all 
antiangiogenic drugs, minocycline may be more beneficial in dogs with early disease, as 
a protective mechanism against metastasis. Yunnan Baiyao is a Chinese herbal 
medication that has been used for its poorly understood anti-inflammatory, procoagulant 
and wound healing properties. In vitro, the medication initiates apoptosis in three 
separate dog HSA cell lines in a time and dose dependent manner. 165 Clinically, no side 
effects are reported and this medication is anecdotally associated with longer survival 
times in dogs treated with surgery with or without chemotherapy. Further studies are 
needed to determine its efficacy.  
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Immunotherapy has been gaining popularity in cancer treatment because of the 
ability to target tumor cells while sparing normal cells, resulting in minimal side-effects 
compared to conventional chemotherapy. Liposome-encapuslated muramyl tripepdife 
phosphatidylethanolamine (L-MTP-PE) is a mixed killed bacterial vaccine. This 
injection is thought to activate macrophages to an antitumor state and to support 
production of anti-tumor cytokines such as IL-6 and TNFα.  A prospective, randomized 
study was conducted with 32 dogs with HSA after splenectomy in two treatment groups. 
The control group received only chemotherapy and had a MST of 143 days while the 
group receiving chemotherapy plus L-MTP-PE had a significantly longer MST of 227 
days. This improved survival time was more apparent in dogs with Stage I disease 
compared to Stage II disease. 166 Excluding doxorubicin, this is the only treatment shown 
to significantly increase survival time in dogs with HSA. L-MTP-PE has not been 
further studied and is unavailable in the United States. An anti-HSA vaccine was 
designed to trigger an antibody response from the host directed against cultured HSA 
cells. In 13 dogs with HSA, when this vaccine was administered with chemotherapy, the 
MST was 182 days. Compared to historic controls, the treatment group had an improved 
survival time but no difference was found in the time to tumor recurrence. This study 
enrolled a small number of dogs and since the rate of adverse reactions was low, more 
studies are needed to determine the clinical benefit of anti-HSA vaccine as an adjunct 
treatment. 167 As we learn more about what is required for the growth and metastasis of 
this tumor, more targeted therapies may be investigated. 
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 In addition to medications and immunotherapy, dietary therapies have been 
developed to slow the progression of cancer in dogs. A commercial dog food designed 
for dogs with cancer contains low carbohydrates, high polyunsaturated omega-3 fatty 
acids and specific amino acids. This diet has been shown to cause less systemic 
inflammation compared to standard commercial dog food diets. When dogs with 
lymphoma were placed on this diet, the chemical indices of inflammation decreased and 
their survival time increased but the food has yet to be studied in dogs with HSA. 168 
Since inflammation is likely important in the pathogenesis of HSA, reducing subclinical 
systemic inflammation by changing the diet may prove beneficial.  
The estimated survival time for dogs with HSA varies slightly with the treatment 
used. Surgery and chemotherapy remain the mainstay of treatment for HSA. Some 
chemotherapeutics may prove to be more effective earlier in the disease process as they 
work by inhibiting migration of tumor cells and formation of new blood vessels, which 
are both required for metastasis.  Since the surgical part of treatment is considered 
palliative care, the focus on quality of life in the postoperative months cannot be 
emphasized enough. If any perioperative variables exist that can improve quality or 
quantity of life for dogs with HSA, further investigation is warranted. 
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CHAPTER II 
 ALLOGENEIC BLOOD TRANSFUSIONS IN DOGS WITH 
HEMANGIOSARCOMA: A RETROSPECTIVE STUDY OF 104 CASES 
 
Introduction 
Hemangiosarcoma (HSA) arises from primitive endothelial cells, has continuous 
contact with circulating blood, and has a high metastatic rate.  169 Dogs diagnosed with 
HSA have a short median survival time (MST) despite surgery and chemotherapy, even 
when gross metastases are not detected at the time of surgery.	7,15,37,49,61,63,156 The MST 
following treatment of HSA has not improved over time despite advances in 
chemotherapeutics.	7,42  Approximately 50% of dogs that are treated for splenic HSA 
with surgery and a variety of chemotherapy protocols are alive at 6 months and 11% are 
alive at 1 year.	42,63 The frequency of disease recurrence despite surgery to remove 
macroscopic disease suggests that micrometastatic disease is present at the time of 
surgery in dogs presenting with HSA.	38 
Some dogs with HSA present on emergency with a hemoabdomen due to a 
ruptured tumor and are often given allogeneic blood products perioperatively to address 
anemic hypoxia and to improve tissue oxygenation.	37,77 Recent retrospective data shows 
that out of 211 dogs receiving allogeneic blood transfusions (ABT) for various reasons, 
transfusion-associated complications occurred in 37% of dogs ranging from a febrile 
reaction to acute kidney and lung injury.	77 Apart from the risk of short-term side effects, 
the use of ABT may carry other long-term risks that are not apparent at the time of 
administration.  
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Possible long-term risks are related to the storage of blood products and the 
immunomodulatory effects seen in ABT recipients. Stored blood products accumulate 
mediators that may be especially detrimental to recipients with preexisting tumor 
burden.	114 Allogeneic blood transfusion-related immune modulation (TRIM) is an 
unintended consequence of ABT that has been well described in humans.	83,114 TRIM 
results in a nonspecific inflammatory response and immune dysfunction, which may 
contribute to tumor progression.	82 In light of the cellular and biochemical changes that 
occur with ABT, several observational studies have been performed in humans with 
various tumor types to determine if ABT administration affects tumor recurrence and 
patient survival. In a prospective study of 339 patients with colorectal cancer, Tartter et 
al. showed that tumor stage and ABT administration were the only factors to 
independently affect survival time after accounting for the other confounding variables 
such as blood loss, tumor differentiation and duration of surgery.	2 Hirano et al. 
compared the 10-year survival rate of colorectal cancer patients who received ABT to 
those who received autologous blood during surgery. The group who received ABT at 
the time of surgery had a significantly shorter tumor-free time interval and lower 10-year 
survival rate, implying long-term consequences of ABT in cancer patients.	144 Meta-
analyses looking at the relationship between ABT and cancer recurrence show that ABT 
is an independent predictor of cancer recurrence.	90,170 
  ABT contributes to perioperative immune dysfunction, inflammation and 
inferior postoperative outcome in human patients resulting in the recommendation to 
perform autologous blood transfusions rather than ABT.	92,95 The effect of ABT 
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administration on outcome in dogs has not been previously investigated. We hypothesize 
that the administration of ABT to dogs undergoing splenectomy for HSA is associated 
with a shorter time to clinical decline.  
Materials and Methods 
An electronic medical record search was conducted to identify dogs undergoing 
splenectomy for a splenic mass between January 2006 to May 2014 at the University of 
Florida and January 2005 to May 2014 at Texas A&M University.  Dogs that underwent 
splenectomy, were diagnosed with HSA based on histopathology, and were discharged 
from the hospital were included. A total of 104 dogs were included, 38 from the 
University of Florida and 66 from Texas A&M University.  Dogs were excluded from 
the study if they did not survive to discharge from the hospital.  
Information obtained from the medical records included: age, sex, breed, 
presence or absence of a hemoabdomen, whether or not ABT was administered, 
presence and location of metastatic disease diagnosed at the time of surgery, if the dog 
received chemotherapy or Yunnan Baiyao, the time to clinical decline, if time to clinical 
decline was related to HSA progression, and the days of survival following surgery. The 
time to clinical decline was determined from the medical record based on client 
communications or recheck appointments at the participating institution or through 
communication with a referring veterinarian. Clinical decline was determined to be 
related to HSA progression based on clinical signs and subsequent diagnostics or 
necropsy findings confirming the presence of concurrent diseases.   
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The presence of metastatic disease at the time of surgery was determined by 
results of preoperative thoracic radiographs and biopsies obtained at surgery. Dogs were 
retrospectively staged into categories first described by Brown in 1985 with stage I 
defined as HSA confined to the spleen, stage II defined as HSA that has ruptured, and 
stage III defined as HSA with multiple gross lesions in more than one organ.	7 
Statistical Analysis 
Disease-free interval following surgery was the primary variable of interest.  For 
each dog, this was defined as the interval between the date of surgery and the date of 
clinical decline.  Dogs that had not experienced clinical decline by study’s end were 
right-censored. 
The Kaplan Meier method was used to obtain univariate descriptive statistics for 
survival data, including the median survival time, and compare the survival experience 
for the enrolled cases by chemotherapy (yes/no), hemoabdomen (yes/no), blood 
transfusion (yes/no), gross metastasis (yes/no), and Yunnan Baiyao administration 
(yes/no). The log-rank test for equality across strata was used to assess whether a 
categorical predictor variable should be included in the final model. A Cox proportional 
hazard model with a single continuous predictor was used to assess cases by age. The 
Wald chi-square test was used to evaluate the association of this continuous variable 
[i.e., age] with time to clinical decline. 
Multivariable Cox regression models were used to analyze the association or 
effect of the potential predictor variables with a p-value of 0.25 or less on univariate 
analysis. Possible interactions were assessed between all predictor variables. The 
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assumption of proportionality was confirmed by including time-dependent covariates in 
the model. Model fit was evaluated using Cox-Snell residuals. Analyses were performed 
using STATA software, Intercooled version 12.0.  
Results 
One hundred and four dogs met the inclusion criteria.  Of the 35 represented 
breeds, mixed breed (n=20), Labrador (n=17), Golden retriever (n=13), German 
Shepherd (n=7) and boxers (n=7) were the most common. The mean age at surgery was 
10.4 years (range, 4.1 to 15.4 years). The sex distribution included intact females (n=5), 
intact males (n=10), spayed females (n=48) and castrated males (n=41). Dogs with 
splenic HSA were classified as clinical stage I in 18/104 (17.3%), stage II in 39/104 
(37.5%) and stage III 47/104 (45.2%) (Table 1).  Of the dogs with distant metastases, 29 
were to the liver, 11 were to the lung, 11 were to the omentum, two were to abdominal 
lymph nodes, two were to the falciform fat, one was to the ilial wing, and one was to the 
subcutaneous tissue. A total of 75/104 (72.1%) dogs presented with a hemoabdomen, 
36/75 (48.0%) of those had gross metastatic disease at the time of surgery. Eleven dogs 
had metastasis to distant organs but did not have a hemoabdomen and were categorized 
to stage III. Except for the four dogs that were alive at the end of the study, all died or 
were euthanized as a result of HSA progression.  
Six months after surgery, 25/104 (24%) dogs had not clinically declined and 
30/104 (29%) were alive. One year after surgery, 9/104 (8.7%) dogs had not clinically 
declined and 13/104 (12.5%) were alive. The mean interval between time to clinical 
decline and time to death was 36 days (range 0 – 1461 days). The time to clinical decline 
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was the same as date of death in 34/104 (33 %) of dogs. Four dogs were alive at the 
completion of the study, two of which were administered ABT, none had gross 
metastatic disease and one received chemotherapy and Yunnan Baiyao.  At the time of 
manuscript preparation, the mean survival time following surgery for the four dogs that 
are still alive is 560 days (range 166 – 1143 days).  
 Stage I Stage II Stage III 
Total dogs N=18 (17%) N=39 (38%) N=47 (45%) 
ABT administration (%) 4 (22%) 29 (74%) 30 (64%) 
Chemotherapy 
[+ABT administration] 
14 
[3] 
17 
[13] 
16 
[15] 
Yunnan Baiyao 
[+ABT  administration) 
4 
[3] 
1 
[1] 
8 
[7] 
Alive at end of study 
[+ABT administration) 
2 
[1] 
2 
[1] 
0 
[0] 
Median time to decline (range) 
[+ABT administration] (range) 
175 (48-481) 
[238] (161-274) 
95  (5-439) 
[89] (5-439) 
60 (1-916) 
[43] (1-916) 
Median survival time 
[+ABT administration] 
193 (48-693) 
[256] (173-274) 
105 (5-1586) 
[100] (5-1586) 
63 (1-916) 
[56] (1-916) 
 
Table 1. Dogs with HSA who survived hospitalization after surgical treatment were 
categorized based on clinical stage. The number of dogs in each stage that were 
administered ABT, chemotherapy and Yunnan Baiyao are reported here. The number of 
dogs in each stage that were administered ABT as well as the other two treatments is 
reported here in brackets. The median time to decline and MST are reported in days. 
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The dogs were divided into groups based on whether an ABT was administered 
while in hospital. Table 2 summarizes the characteristics of the two groups. The groups 
were similar in age and sex distribution. As expected, ABT administration was more 
common in dogs that presented with a hemoabdomen. In the present study population, 
75/104 (72%) of dogs with HSA presented with hemoabdomen and 59 of those 75 dogs 
(78%) were administered ABT. The groups had a similar prevalence of gross metastatic 
disease on presentation. A similar proportion of dogs received chemotherapy in each 
group. For dogs not given ABT (n=37), the median time to decline was 120 days (range 
38 - 916 days) and MST was 136 days (range 41 - 916 days). For dogs who received 
ABT (n=67), the median time to decline was 76 days (range 1 – 836 days) and the MST 
was 97 days (range 1-1586 days).  
 
 
No ABT 
N=37 
ABT 
N=67 
Mean age in years (range) 11.1 (7.4 – 15.4) 10.1  (4.1-14.7) 
Hemoabdomen 15 (41%) 60 (90%) 
Gross metastatic lesion 13 (35%) 34 (51%) 
Chemotherapy 16 (43%) 31 (46%) 
Yunnan Baiyao 2 (5%) 11 (16%) 
Median time to decline (range) 120 (38 - 916) 76 (1 - 836) 
Median survival time (range) 136 (41 - 916) 97 (1 - 1586) 
 
Table 2. Dogs treated for HSA were divided into groups based on if an allogenic blood 
transfusion was administered at the time of surgery. The number of dogs in each 
category is reported. The median time to decline and MST are reported for each group in 
days. 
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The Kaplan Meier method showed that ABT administration (p=0.0145), 
chemotherapy administration (p=0.0612), the presence of a hemoabdomen (p=0.0009), 
the presence of gross metastatic lesions (p=0.0009) and the administration of Yunnan 
Baiyao (p=0.162) were all associated with time to disease progression using univariate 
analysis. Age of the dog at the time of surgery (p=0.588) was not associated with time to 
disease progression.  The administration of Yunnan Baiyao decreased the time to decline 
by 64% (p=0.008, CI 23-83%). 
Multivariable Cox regression model was used to determine the effect of these 
predictor variables on time to tumor progression. No interactions were found between 
predictor variables.  While holding all other variables constant, ABT administration 
increased the time to decline by 69% (p=0.042, CI 2-179%). The presence of gross 
metastasis increased the time to decline by 146% (p=0.00, CI 60-279%). The presence of 
metastatic lesions indicated a shorter time to disease progression when compared to the 
presence of a hemoabdomen in this study (OR 2.4 versus 1.7). The administration of 
chemotherapy decreased the time to decline by 33% (p=0.063, CI -2%, 67%).  
The chemotherapy protocol consisted of doxorubicin for most dogs but other 
protocols were used for a variety of reasons.  Reasons for a non-doxorubicin protocol 
that were recorded in the medical record included preexisting cardiac disease and drug 
intolerance. Yunnan Baiyao was prescribed to 13 dogs, five of which had presented with 
a hemoabdomen. Because of the small number of dogs that received Yunnan Baiyao and 
the uncertainty of how often this was offered as a treatment option, this variable was not 
included in the multivariate analysis.  
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Discussion 
This study sought to determine if ABT administration has clinically relevant 
consequences for dogs diagnosed with HSA. In this study population, the use of ABT 
was associated with a shorter time to clinical decline in dogs with splenic HSA. The 
shortened disease-free interval found in dogs receiving ABT is possibly due to the 
effects of TRIM in dogs with cancer, the negative effects associated with blood storage, 
the advanced disease in dogs requiring ABT, or, likely, a combination of factors. 
Our study demonstrates a shorter time to clinical decline in dogs with HSA that 
are administered an ABT. If this relationship is causal, it may be explained in part by the 
effects of TRIM. TRIM refers to the immunomodulatory and pro-inflammatory changes 
in a recipient following ABT administration. In human patients, TRIM has been 
implicated in decreased post-surgical disease-free interval and survival time for a variety 
of tumor types.	2,89,144,170 The effects of TRIM may be especially relevant in recipients 
with metastatic disease at the time of surgery.	171 Studies have shown that dogs with 
HSA often have either gross or micro-metastases at the time of diagnosis and 45% of the 
dogs in the present study were diagnosed with gross metastasis at the time of surgery. 
Therefore, if TRIM affects dogs like people, we expect this group of dogs to be 
especially susceptible to the immunomodulatory effects of ABT. 
Since the clinical effects of TRIM have been defined in human medicine, the 
cellular and biochemical changes associated with ABT in humans and lab animals have 
been studied in order to elucidate the mechanism by which the immunomodulatory 
effects occur. The mechanisms of TRIM are currently divided into two overlapping 
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categories: the pro-inflammatory effects and immunomodulatory effects, both of which 
may support metastasis.	33,83 The administration of ABT in human gastrointestinal cancer 
patients causes depressed natural killer cell activity, a shift of T-cell phenotype from T-
helper 1 to T-helper 2, elevated interleukin-10 (IL-10) levels, decreased interleukin-2 
(IL-2) levels and decreased immunoglobulin levels in the recipient. These changes 
collectively reflect a dampened innate and humoral immune function.	92 Natural killer 
cells and the cytokines produced by T-helper 1 cells have anti-tumor activity. T-helper 2 
cytokine production can be initiated directly by tumor cells and promotes tumor 
invasiveness and metastasis.	32 IL-10 levels are elevated following ABT, which mediates 
the shift from a T-helper 1 to T-helper 2 phenotype. Following ABT, plasma IL-2 levels 
are significantly decreased.	1 IL-2 normally enhances T-cell, B-cell and natural killer cell 
function as well as activates macrophages to kill tumor cells.	33 Prostaglandin E2, an 
immunosuppressive prostanoid, is elevated in ABT recipients.	93 These immunologic 
changes seen in human cancer patients with ABT use warrants further study into the 
clinical consequences of immunomodulation in dogs with HSA.  
The shortened disease-free interval found in dogs receiving ABT is possibly due 
to the negative effects associated with blood storage. In addition to diminished function 
of stored RBC, administration of stored blood products is associated with dramatic 
vascular changes in experimental dogs. Dogs given 21-day-old autologous blood showed 
significant microscopic and macroscopic evidence of pulmonary edema and perivascular 
hemorrhage compared to those given fresh autologous blood.	103 Importantly, the 
changes in the lung were subclinical and would likely be missed in a hospitalized dog. 
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Because of the propensity for HSA to metastasize to the lungs, we suspect that ABT-
induced pulmonary vascular changes may be especially relevant to dogs undergoing 
treatment for HSA. Inflammation and inflammatory mediators play a role in cancer 
metastasis.  Specifically, vascular endothelial growth factor, interleukin-8 and 
microparticles may be especially relevant to dogs with HSA receiving stored ABT. Each 
of these substances increases in stored blood.  Further, each of these substances has been 
linked to cancer development or metastasis and inflammation, suggesting that “storage 
lesion” may be a clinically significant downside to giving stored blood products to dogs 
with HSA. However, the relationship between storage lesion and tumor progression has 
not been explored in dogs. 
The presence of a ruptured tumor and gross metastasis in the abdomen were each 
independently associated with shorter time to clinical decline in this study population. 
Clinical staging for dogs with HSA was first described by Brown in 1985.	7 Stage I 
indicates a tumor confined to the spleen, Stage II indicates a ruptured tumor or local 
lymph node metastasis and Stage III indicates a tumor invading other tissues or 
macroscopic distant metastasis. Although stages are described, controversy exists over 
whether stage predicts outcome. Several retrospective studies with heterogeneous patient 
populations have shown that survival time for dogs with HSA is not consistently 
influenced by the stage of disease at presentation.	38,51,61,156 However, one prospective 
and one retrospective study of dogs with splenic HSA showed that the presence of a 
hemoabdomen at the time of diagnosis is associated with shorter survival time.	38,42  The 
present study demonstrates that dogs with metastatic lesions and hemoabdomen have a 
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shorter time to clinical decline. Furthermore, the presence of metastatic lesions indicated 
a shorter time to disease progression when compared to the presence of a hemoabdomen 
in our study (OR 2.4 versus 1.7). This result suggests that in dogs with HSA, staging 
influences time to disease progression and prognosis. We expect that dogs with stage I 
and II HSA had a longer time to disease progression compared to stage III because they 
presented with a heavier tumor burden.  
While the dogs in the current study demonstrated a decreased time to disease 
progression when ABT was administered, the administration of chemotherapy was 
associated with significantly increased survival time. Despite the heterogeneity of the 
chemotherapy protocols, our findings agree with the current literature that chemotherapy 
administration significantly increases MST in dogs with hemangiosarcoma.	12,60,157  No 
specific chemotherapy protocol has been determined superior in treating dogs with 
hemangiosarcoma.	42,158  For this reason, the type of chemotherapy administered was not 
included in the analysis. 
The effect of Yunnan Baiyao was evaluated to determine if administration is 
associated with improved outcome in dogs with HSA.  Yunnan Baiyao is a Chinese 
medication and is purported to mitigate bleeding and inflammation. The mechanism of 
action of the medication is unknown, and any explanation of this finding is speculative. 
However, anti-tumor effects of Yunnan Baiyao have been studied and the medication has 
been shown to slow the growth of cultured HSA cells in vitro. 165 Our data shows slower 
time to disease progression associated with the administration of Yunnan Baiyao to dogs 
presenting with HSA. The beneficial effect may be due to the anti-inflammatory, 
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hemostatic, pain relieving, or wound healing properties of the medication or due to a 
Type I error because of the small number of study dogs that received this treatment.  
Study Limitations 
Several limitations exist in this study.  The first is that the mechanism behind a 
shorter time to disease progression in dogs administered ABT is not identified in this 
study.  While possibilities proposed in human medicine are presented, disease severity or 
other undefined confounding variables may necessitate ABT in dogs and may represent 
an unidentified underlying cause of shorter time to disease progression. Evidence-based 
transfusion guidelines (“triggers”) for dogs with non-traumatic hemoabdomen do not 
exist. Individual clinicians were responsible for determining whether or not ABT were 
administered in this study. While ABT use may be a surrogate marker for the presence 
more severe disease, our statistical analysis showed that ABT was an independent 
predictor of decreased time to disease progression and that no interaction was found 
between predictor variables. Interestingly, 7 (7/29 = 24%) of the dogs without a 
hemoabdomen were given ABT. The reason for ABT administration in dogs without 
hemoabdomen is unclear from the medical record and demonstrates the variety of 
“transfusion triggers” among clinicians. Previous studies have suggested that liberal 
ABT use can result in negative consequences including non-survival.	77 Human studies 
show that the use of ABT in critical patients is an independent predictor of morbidity 
and mortality and that liberal transfusion triggers may negatively affect patient outcome.	
71,72 A causal relationship between ABT use and decreased time to disease progression is 
impossible to prove in this study.   
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An additional limitation is that a variety of different allogeneic blood products 
were administered to the dogs in our study including: packed red blood cells, fresh 
whole blood and fresh frozen plasma.  The contribution of specific blood components to 
TRIM and storage lesions are not well-defined in dogs. The effects of TRIM may be 
mediated by WBC-derived cytokines or soluble peptides found in plasma.	83  
Additionally, allogeneic fresh frozen plasma has been shown to increase tumor-
promoting factors such as TNFα, IL-10, contain growth factors such as insulin-like 
growth factor and promote tumor growth in nude mice.	172,	173,174  Because of the existing 
evidence that any component of blood may contribute to the inflammatory and 
immunomodulatory effects of ABT, dogs given any type of allogeneic blood product 
were grouped together. Further, the duration of pre-transfusion blood product storage 
varied in the study population and this may have affected our results since blood storage 
is associated with clinically relevant consequences.  
Other limitations are inherent to the retrospective nature of the study. The data 
collection is reliant on the accuracy and completeness of medical records. Omission of 
information from owner-reported history or medical records may have affected the 
results. For example, the number of dogs who had a ruptured tumor and spontaneous 
resolution of a hemoabdomen at home is unknown. Evidence of prior hemorrhage was 
not recorded from surgery reports. In these instances, the dog may have been 
inaccurately categorized as having stage I disease. Many unknown perioperative clinical 
factors may contribute to HSA recurrence such as: degree of resectability of the tumor, 
the presence of postoperative complications and concurrent disease. The genetic, 
 49 
 
biochemical and microenvironmental factors of each individual tumor may also affect 
outcome and were not accounted for in this study. Additionally, including data from two 
institutions allowed for a heterogeneous sample, the variability between clinical 
variables at the two locations is not defined. The individual owner’s decision to pursue 
treatment may be influenced by an unknown number of factors existing at the time of 
presentation and this may affect the population of dogs in our study.  Time to disease 
progression was used as an outcome measure rather than mean survival time to reduce 
the variability associated with owner’s decision to euthanize.  
The biochemical and clinical consequences of ABT in dogs are incompletely 
understood at this time. These data argue for the study of an evidence-based transfusion 
trigger point and the consideration of exploring alternative practices in appropriate 
clinical patients. In order to determine if the administration of ABT directly affects 
disease progression in dogs with HSA, a prospective randomized control study is 
required. Since withholding blood products from a patient in need is unethical and not 
advised, an alternative to ABT is required. Autotransfusion may be used for dogs 
needing to improve tissue oxygen delivery in the control group. Bower has shown that 
intraoperative cell salvage is a practical option for human cancer patients; however 
neoplasia remains listed as a contraindication for autotransfusion in veterinary literature.	
121,146,	175 The safety of this blood conservation technique must be established for dogs 
with HSA before being used in a clinical setting.  
In conclusion, the dogs included in this study that were administered an ABT had 
accelerated disease progression compared to dogs that were not administered ABT. 
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Because the use of ABT in our study was associated with the presence of advanced 
disease, we cannot exclude the possibility that ABT is a surrogate marker of a 
hemoabdomen, less stable patients and possibly more biologically aggressive disease. 
Confounding our retrospective observations is the inability to control for disease 
severity. If the apparent relationship is causal, ABT may contribute to progression of 
HSA because of the consequences of TRIM, storage lesion or a combination of factors. 
The tumor-promoting effects of ABT have been demonstrated in experimental animal 
models but the clinically relevant consequences for dogs with HSA have yet to be 
proven.	171 Future prospective studies should be aimed towards determining whether 
ABT affects disease progression for HSA patients when compared to other methods used 
to improve tissue oxygenation.  
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CHAPTER III 
 THE ABILITY OF A CELL SALVAGE SYSTEM AND LEUKOCYTE 
REDUCTION FILTER TO REMOVE HEMANGIOSARCOMA CELLS FROM 
DOG BLOOD 
 
Introduction 
 Hemangiosarcoma (HSA) is the most common splenic tumor in dogs and is the 
most common cause of non-traumatic hemoabdomen in dogs.	169,	37 Dogs with HSA 
frequently present on an emergency basis due to clinical signs related to a ruptured 
tumor. A hemoabdomen can result in hemorrhagic shock and some dogs require blood 
transfusions to address the blood lost into the abdomen and surgery to remove the 
bleeding tumor. Allogeneic blood transfusion (ABT), specifically packed red blood cells 
(pRBC), are the most commonly used blood products in veterinary medicine.	176  The 
goal of administering pRBC is to improve oxygen delivery to tissues by increasing 
hemoglobin levels.	65,68 
 Although ABT administration can be lifesaving when indicated, recent advances 
in human medicine have questioned the liberal use of ABT. Two research groups have 
prospectively demonstrated that as the quantity of ABT increases, patient morbidity and 
mortality each increase independently of other variables.	71,72 The long-term 
consequences of ABT administration are becoming more apparent in patients with 
cancer.	1 In one prospective cohort study, human patients that received autologous blood 
transfusions during hepatocellular carcinoma resection had a significantly longer time to 
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tumor recurrence and a higher 10-year survival rate compared to the patients that 
received ABT.	144  
The known disadvantages of ABT administration in dogs include: the 
requirement for a blood bank or on-site donors, the time associated with blood typing 
and cross matching, and a 37% incidence of transfusion-related complications.	77  The 
oxygen carrying capacity of stored red blood cells (RBC) diminishes over time.	76 
Furthermore, immunomodulation is found in human cancer patients following ABT 
administration.	114  In an attempt to avoid the side effects of ABT, alternative methods to 
restore tissue oxygenation in the face of blood loss have been explored.  
Intraoperative cell salvage (IOCS) for autotransfusion was first described by 
Highmore in 1874 as a lifesaving measure for obstetrics.	117 Since then, the technique has 
evolved and is now used for a variety of human surgeries, including oncologic surgeries.	
119,146 IOCS has been used successfully as a blood conservation technique to address 
non-neoplastic hemorrhage in dogs but has yet to be studied for oncologic surgery.	120,122 
Albeit a controversial topic, recent human literature advocates for use of IOCS oncologic 
surgery.	135,177,178 Although IOCS use may even provide superior outcomes for human 
oncologic surgery, neoplasia is listed as a contraindication for the use of IOCS in the 
veterinary literature.	122,179  
The concern for returning tumor cells to the systemic circulation and iatrogenic 
tumor metastasis exists with IOCS use in dogs presenting with acute, non-traumatic 
hemoabdomens since about 80% of this population are diagnosed with cancer.	37 
However, the use of a leukocyte reduction filter (LRF) before returning the salvaged 
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blood to the patient may alleviate this theoretical concern. The LRF has been shown to 
remove a variety of tumor cell types from saline, donated blood and intraoperatively 
salvaged human blood.	126,128-132,135,136,177,178   
The goal of this study is to determine the ability of IOCS with LRF to remove 
HSA cells from dog blood ex vivo. This technique has the potential to serve as an 
alternative to ABT. We hypothesize that LRF in combination with the IOCS system will 
remove detectable HSA cells from both culture media and dog blood samples. To test 
this hypothesis, we used flow cytometry, RT-PCR and cytological examination to 
determine the presence of cultured HSA cells at various points in IOCS and LRF 
processing.  
Materials and Methods 
An established HSA cell line, DEN-hemangiosarcoma, was used for this 
experiment.	180 HSA cells were maintained at 37°C and protected from light before use. 
The cells were cultured in monolayer and were detached using 0.25% trypsin (Lonza, 
Houston, TX). For the first portion of the study, the cells were stained using PKH26 Red 
Fluorescent Cell Linker Kits for General Cell Membrane Labeling, (PKH26GL, Sigma-
Aldrich, St. Louis, MO) according to manufacturer instructions. RBC lysis buffer 
(eBioscience, San Diego, CA) was added to a sample of the cells then the cells were 
examined visually for morphologic evidence of damage.  The cells were counted using a 
cellometer before dilution. 
Prior to assessing the ability of LRF and IOCS to remove the HSA cells, we 
tested the ability of cytology, flow cytometry and RT-PCR to detect small numbers of 
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HSA cells. Briefly, HSA cells that were stained with PKH26 were used to create a 50 
cell / mL solution in culture media.  This solution was tested with RT-PCR, flow 
cytometry and cytological examination by standard technique detailed below. 
Part 1  
The ability of a LRF to remove HSA cells from solution was evaluated. Briefly, 
35 mL of a 1,000,000 cell / mL solution of PKH26-stained HSA cells was created in 
culture media.  The solution was added to a sterile transfer bag (Terumo Corporation, 
Tokyo, Japan) then processed through the Leukocyte Reduction Filter for 
Intraoperatively Salvaged Blood (RS1 Haemonetics Manufacuturing Inc., Braintree, 
MA) using a pressure bag under 300 mmHg. The post-LRF filtrate was collected in a 
second sterile transfer bag. Samples were obtained pre and post-LRF from the two 
transfer bags. Samples of 5 mL were collected in EDTA-tubes for cytological 
examination and samples of 2 mL were collected in Eppendorf tubes (VWR 
International, Houston, TX) for RT-PCR and flow cytometry. Time to perform filtration 
was recorded. The steps of Part 1 were repeated 3 times obtaining the same samples each 
time. 
Part 2  
Fresh, whole dog blood anticoagulated with heparin was obtained from a 
commercial blood bank within 24 hours of collection (Whole Canine Blood, Animal 
Blood Bank Resources , Stockbridge, MI). In a sterile bowl, 300 mL of whole blood was 
mixed with a solution of culture media containing 300 million HSA cells for a final 
concentration of 500,000 HSA cells / mL to represent abdominal hemorrhage 
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encountered during surgery for ruptured HSA.	15 The blood/HSA cell mixture was 
processed through the Fresenius C.A.T.S Continuous Autotransfusion System 
(#9CAA0574 Fresenius Kabi AG, Ban Homburg, Germany), using previously described 
techniques.	120,128  The blood/HSA cell mixture was suctioned from a sterile bowl using a 
sterile double lumen suction tip with heparinized saline, as would be done clinically.	149 
The mixture was collected in a cardiotomy reservoir with a 140 µm filter and centrifuged 
to separate RBC from other blood components. In the centrifuge, the healthy RBC settle 
to the bottom while the plasma, a portion of the white blood cells (WBC), platelets, free 
hemoglobin, cell debris, medications, activated clotting factors and wash fluid are 
removed with the supernatant.	120,122 When the cells in the centrifuge reached a packed 
cell volume (PCV) of about 60%, they were washed with saline and pumped into a 
collection bag from the IOCS system. The washed pRBC were processed through the 
LRF which was primed with 35 mL of sterile saline. Four separate samples were 
collected at different times during the IOCS process.  Sample 1 was collected from the 
sterile bowl prior to IOCS system processing, sample 2 was collected after IOCS system 
processing, sample 3 was collected after LRF processing and sample 4 was collected 
from the discarded saline used to wash the RBC (Figure 1). Samples of 5 mL were 
collected in EDTA-tubes for cytological examination. Samples of 2 mL for RT-PCR and 
flow cytometry were collected and immediately RBC lysis buffer was added. This 
process was repeated for three trials on different days with sterile supplies and a 
different dog’s blood. The duration of processing through the IOCS system and duration 
of processing through the LRF were recorded.  
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On the second and third trials of the IOCS and LRF system, the four samples 
collected in EDTA-tubes were pelleted and frozen at -80 degrees Celsius until testing 
using RT-PCR and flow cytometry. The samples were thawed at 37 degrees Celsius in a 
water bath immediately before RT-PCR and flow cytometry.  
 
Figure 1. IOCS with LRF and sampling locations 
 
Cell Detection Methods 
RT-PCR Part 1: A total RNA sample was obtained from PKH26-stained HSA 
cells. The cells were lysed and RNA was extracted using the RNAqueous®-Micro Total 
RNA isolation kit (Ambion, Grande Island, NY). The RNA preparation was treated with 
TURBO DNA-free™ Kit (Ambion, Grande Island, NY) to remove any remaining traces 
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of DNA. RNA quantity was assessed using a NanoDrop spectrophotometer in 
preparation for cDNA synthesis. cDNA was synthesized using 35 ng of RNA and the 
qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD). The thermocycler 
used for cDNA synthesis was an Eppendorf Mastercycler epgradient S (Eppendorf, 
Hamburg, Germany). The expression of von Willebrand Factor was confirmed through 
RT-PCR by mixing one-tenth of the synthesized cDNA, SsoFast™ qPCR Mastermix 
(Bio Rad, Hercules, CA), and 1 µM of both forward (5’-
TGACAAGGTGTGTGTCCACC-3’) and reverse (5’-ACAGGCAGTTGTCCTCACAG-
3’) primers. RPS19 was amplified as an internal control. All reactions were performed in 
triplicate. The thermocycler used for RT- PCR was a Bioradicycler IQ (Biorad, 
Hercules, CA).  
RT-PCR Part 2: The same process as above was performed with two exceptions: 
HSA cells were not PKH26-stained and RBC lysis was performed prior to RNA 
extraction.   
Flow Cytometry Part 1: PKH26-stained HSA cells were mixed with 100 µL of 
concentrated unstained HSA cells to increase the detection yield of flow cytometry. 
Acquisition of the flow cytometric data was performed using a MoFlo Astrios and the 
Summit software package (Beckman Coulter, Brea, CA).  Analysis of the data was 
performed using FloJo X software package (Tree Star Inc., Ashland, OR).  The samples 
were tested for 2 replicates. HSA cell fragments and cell aggregates were included in the 
data collection. This method was repeated for the pre- and post-LRF samples in Part 1. 
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Flow Cytometry Part 2: The samples 1-4 from Part 2 were washed with PBS to 
remove residual serum, incubated in 1 mM EDTA for 5 min, and detached by gentle 
scraping with a sterile rubber policeman. Staining buffer consisted of PBS with 0.5% 
bovine serum and 0.1% sodium azide. One million cells were incubated with anti-
CD51/CD61 antibody (2 mug/ml, EMD Millipore, Billerica, MA), anti-CD18 antibody 
(0.5 mg/mL, AbdSerotec, Raleigh, NC), or anti-CD117 antibody (2 mug/ml, 
eBiosciences,San Diego, CA) for 30 min at 4°C. Cells were then washed four times in 
staining buffer and incubated with a goat-anti-mouse IgG/IgM antibody conjugated to 
Alexa 488, PE, and Alexa 647  for 20 min. Cells were again washed four times in 
staining buffer and then fixed in 2.5% neutral buffered formalin. Samples were kept at 
4°C protected from light until analysis using a Beckman Coulter MoFlo Astiros FACS 
instrument (Beckman Coulter, Berea, CA, USA) running the Summit software package.
15 The flow data analysis was conducted using FlowJo 10 (Tree Star Inc., Ashland, OR).15
Cytology Part 1 and Part 2:  A board-certified clinical pathologist (G.L.) 
prepared and examined three slides of each sample using a method modified from 
Catling et al.	136 The clinical pathologist was blinded to whether the sample was pre- or 
post-LRF.  The aliquot of each sample was concentrated by centrifugation at 3000 rpm 
for 10 minutes.  The supernatant was removed and the remaining cells and solution were 
re-suspended in 5 mL of phosphate buffered saline.  Five drops of a RBC lysing agent 
(ZAP OGLOBIN II Lytic Reagent, Beckman Coulter, Ireland) were added to the re-
suspended liquid, which was re-centrifuged then the supernatant was decanted to leave 1 
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mL of liquid.  The tube was vortexed for 30 seconds to re-suspend the cells.  Three 
cytocentrifuge funnel/slide combinations were loaded with 200 µL of the solution.  
Cytocentrifuge preparations were centrifuged at 1500 rpm for 10 min.  Preparations were 
stained using a modified Wright’s stain (Wescor, Logan, UT) and evaluated for the 
presence of HSA cells. The number of whole cells and number of cell fragments present 
were recorded.  Slide preparations were made immediately after sample collection.  
Leukocyte Reduction Filter Evaluation 
Filter material was removed from the plastic housing and placed in 10% neutral 
buffered formalin for more than 24 hours. Following fixation, the filter material was 
dehydrated in a series of graded ethanol.  The layered filter material was separated to 
allow representative evaluation. A low-vacuum scanning electron microscope2 at 5 to 15 
kV was used to obtain images of HSA cells captured within the filter material. Images 
were captured at magnifications of 300x to 3000x. 
Statistical Analysis 
Descriptive statistics were generated for time for processing using JMP Pro 11 
(SAS Institute Inc, Cary,NC).  
Results  
RT-PCR, flow cytometry and cytological examination were all able to detect the 
presence of PKH26-stained HSA cells in the 50 cell/ml solution.  Therefore, all three 
tests were performed to evaluate samples in both part 1 and part 2 of the study. 
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Part 1 
Analysis by RT-PCR, flow cytometry and cytological evaluation all detected the 
presence of PKH26-stained HSA cells in the pre-LRF samples.   Following LRF 
processing, RT-PCR, flow cytometry and cytological evaluation did not detect any 
PKH26-stained HSA cells in the post-LRF samples.  
The mean duration required for 55 mL of the 50 cells/mL of culture media 
solution to pass through the LRF under 300 mmHg of pressure was 7.6 s or 7.2 mL/s 
(range, 7.4-7.9 s).  
Part 2 
When the HSA cells were suspended in dog blood, all three methods of detection 
revealed the presence of HSA cells in sample 1 (control).  Following IOCS (sample 2), 
RT-PCR, flow cytometry and cytological evaluation detected HSA cells. Additionally, 
flow cytometry detected signals consistent with cell fragments and cell fragment 
aggregates in samples following IOCS. Following LRF (sample 3), HSA cells were not 
detected by RT-PCR or cytological analysis.  Flow cytometry did not detect HSA cells 
in the post-LRF sample for the first trial. Flow cytometry detected the presence of 
approximately 16 HSA cells and 56 HSA cells in post-LRF samples in the second and 
third trials, respectively. When the discarded wash solution (sample 4) was evaluated, 
RT-PCR and cytological analysis did not detect any HSA cells. Flow cytometry did not 
detect HSA cells in sample 4 for the first trial. Flow cytometry determined the presence 
of approximately 14 HSA cells and 94 HSA cells in the wash solutions of the second and 
third trials, respectively (Table 3) 
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Table 3. Results from three cell detection methods. Each plus sign (+) denotes HSA 
cells were detected from one trial. Each negative sign (-) denotes no HSA cells were 
detected from one trial. 
The mean time for IOCS processing was 15 min (range 13-17 min) or 0.64 mL/s 
and the mean time for LRF processing using gravity was 6 min (range 3-10 min) or 0.43 
mL/s.   
The filter imaging revealed cells adhered to the fibers of the filter (Figure 2). 
The cells appeared intact.  
Discussion  
The findings of this study indicate that IOCS in combination with LRF is able to 
remove a majority of the 300 million HSA cells added to the dog blood. The IOCS 
process filters, washes, and centrifuges the blood, however, is inadequate for HSA cell 
removal as HSA cells were detected after the IOCS processing. Evaluation of the sample 
of pRBC following IOCS (sample 2) in Part 2 of the experiment revealed the presence of 
HSA cells. A small number of HSA cells were detected in the wash solution in two of 
Cell 
Detection 
Method 
Sample 1 
Pre-IOCS 
Sample 2 
Post-IOCS 
Sample 3 
Post-LRF 
Sample 4 
IOCS 
Wash 
Flow 
cytometry 
+   +   + +   +   + -   +   + -   +   + 
RT-PCR +   +   + +   +   + -   -   - -   -   - 
Cytologic 
examination 
+   +   + +   +   + -   -   - -   -   - 
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the three experimental trials, which shows that the IOCS system alone is relatively 
ineffective at removing HSA cells during the saline wash.  We suspect that the LRF is 
responsible for the majority of HSA cell removal.  
Figure 2. Scanning electron micrograph of a used LRF 
Flow cytometry detected HSA cells in the post-LRF filtrate (sample 3) in 2 of the 
3 trials.  HSA cells may have passed through the LRF if the filter material has a limit to 
the number of cells that it can trap and that number was exceeded in the second and third 
trial. Previous studies have shown that with high concentrations of cultured tumor cells, 
the LRF fails to remove all detectable tumor cells.	127,129 Fruhauf et al. found that the 
depletion capacity, or percent of cells removed by the LRF, of a LRF using cultured 
colorectal carcinoma cells and primary tumor cells in human blood was 99.6% to 100%.
130 Because flow cytometry cannot be used to accurately quantitate cells, we cannot 
calculate the precise depletion capacity of the LRF in this experiment. However, visual 
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comparison the scatterplots from the pre- and post-LRF samples shows a drastic 
reduction of cell number in the area gated for HSA cells (Figure 3). In a different study, 
hepatocellular carcinoma cells were detected post-LRF when a tumor ruptured in 
surgery.  The authors theorized that the filter was overwhelmed allowing overflow of 
tumor cells.	127 In the present study, the number of tumor cells may have overwhelmed 
the filters, allowing overflow. It is difficult to explain why HSA cells were detected in 
only two of the three trials.   
 The LRF removes WBC and tumor cells. Therefore, increasing either WBC or 
tumor cell numbers would theoretically contribute to overwhelming the filter. A WBC 
count was not performed on the blood used in this study, so we are unable to determine 
if a slightly higher WBC count was present in blood from trials 2 and 3, resulting in 
“spill over” of HSA cells into the post-LRF sample. However, a study using human 
blood showed that the patient’s WBC count did not correlate with the ability of the LRF 
to remove tumor cells.	181  
 Alternatively, other differences in the blood could have contributed to the 
detection of HSA cells in two of the three trials.  Brownlee et al. found that the 
efficiency of the LRF to remove dog WBC increased when the dog blood was cooled.	112  
Increasing blood viscosity with lower temperatures may slow the flow and increase the 
contact time between the cells and the filter material. If this speculation is true, other 
factors that increase blood viscosity, such as PCV, would be expected to change the 
efficiency of the LRF as well.  The temperature of the blood/HSA cell mixture was not 
measured in our study design but all trials were performed at ambient temperatures. The 
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variation in temperature, viscosity and PCV of the blood/HSA cell mixture in each of the 
three trials may have contributed to the detection of HSA cells by flow cytometry in two 
of the three trials.  
 A discrepancy between the three methods of cell detection was found in the post-
LRF and wash fluid samples for the second and third IOCS and LRF trials. Flow 
cytometry detected the presence of HSA cells in both of the samples but RT-PCR and 
cytological examination did not detect HSA cells. RT-PCR is used to detect small 
amounts of DNA and is considered a sensitive method of cell detection. With low 
numbers of HSA cells, false negative results are possible with RT-PCR if the DNA was 
damaged during sample handling. False positive results are possible with flow 
cytometry.  False positive results could have occurred if HSA cells from a previous run 
were stuck to the plastic tubing inside the analyzer despite efforts to flush the tubing of 
all debris between samples. Further, flow cytometry detects surface markers in cell 
membrane.  It is possible that clumps of fragmented cell membrane were interpreted as 
cells in the second and third trials.  However, because of the number of cells found, we 
consider this possibility unlikely. 
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 Figure 3. Flow cytometry results from Part 2 second trial. A marked reduction in 
HSA cell numbers is found in the post-LRF sample (sample 3). A small number of HSA 
cells are found in the wash fluid obtained from the IOCS processing. 
 
 The number of tumor cells expected to be encountered during surgical treatment 
for HSA is unknown. The number of HSA cells to be processed through the IOCS and 
LRF in this experiment is based on the findings of Lamerato, Kozicki et al. An estimated 
0.8% of all circulating nucleated cells in dogs with HSA are tumor-like cells.	15 In a dog 
with a high-normal WBC count of 136 WBC/µL of blood, about 136,000 HSA cells/mL 
of blood are circulating in dogs with HSA. This experimental design tested the ability of 
the LRF to remove over 2000 times the estimated amount of circulating HSA cells in 
attempt to recreate the clinical scenario of a dog undergoing surgery to address a 
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ruptured tumor. Specifically, in Part 1, 35 million cells were added to culture media and 
processed through the LRF.  No HSA cells were detected following LRF processing in 
Part 1. In Part 2, a total of 300 million HSA cells were added to dog blood and processed 
through the IOCS and LRF. The administration of ABT has a negative effect on the 
success of cancer treatment in some human patient populations.	3,90,	2 When used in place 
of ABT, autologous blood transfusions may ameliorate some of the negative effects on 
tumor progression seen with ABT administration. A randomized controlled trial of 
patients with colorectal tumors compared disease-free survival rates between patients 
randomized to receive ABT or autologous pre-donated blood during curative-intent 
surgery. Results showed ABT administration and tumor stage were the only two 
variables to independently negatively affect disease-free survival.	89  When compared to 
ABT administration, IOCS use was shown to be associated with an equal survival time 
in human patients with late stage hepatocellular carcinoma but an improved survival 
time when used in patients with early stage hepatocellular cacinoma.	139,144 While a clear 
benefit has not been proven in all patient populations, IOCS use has been deemed safe 
for use in oncologic surgery for humans.	146,19 
 The mechanism by which ABT affects disease progression in cancer patients is 
poorly understood and multifactorial but is believed to involve transfusion-related 
immunomodulation (TRIM) and the negative effects seen with storage of blood 
products.	114 TRIM refers to the subclinical changes in the immune system following the 
administration of ABT, which may be especially important in cancer patients. Patients 
with malignant gastrointestinal tumors who received ABT showed impaired tumor cell 
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recognition and killing compared to those patients receiving autologous blood.	1  These 
tumor-promoting effects of ABT are seen across species as ABT has been shown to 
enhance implanted tumor growth in mice but the clinical consequences of TRIM in dogs 
have not been described.	88  
 The storage of blood products may also contribute to the negative clinical effects 
seen with ABT use, and may be especially relevant in HSA patients.	76,96,104  Stored dog 
blood accumulates mediators which have been shown to enhance HSA growth and 
survival, such as VEGF, IL-8 and microparticles.	21,31,105-107 Microparticles are cell 
fragments that have been recently recognized for their involvement with inflammation, 
tumor progression, angiogenesis and metastasis.	108 The clinical consequences of the 
presence of these mediators are unknown. While the benefit of ABT administration in 
dogs with life-threatening hemorrhage and anemic hypoxia cannot be denied, these 
potentially tumor-promoting mediators are inadvertently administered to dogs 
undergoing surgery for HSA. Currently, alternative methods to address hemorrhage and 
anemic hypoxia in dogs with HSA are limited.  
 IOCS for dogs with cancer has yet to be explored as an alternative to ABT 
administration.  The previously described veterinary use of the IOCS did not include a 
LRF.	122,149,182  The viability of canine RBCs is normal immediately after LRF 
processing.	112 Although not yet studied in dogs, human RBC salvaged during spinal 
surgery have a normal lifespan of 30 days after IOCS processing.	123 Compared to 
allogeneic blood products, intraoperatively salvaged blood has been shown to have 
increased longevity, increased 2,3-disphosphoglycerate levels, increased adenosine 
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triphosphate levels and improved conformability, which is important for capillary 
circulation.  For these reasons, tissue oxygen delivery should be greater when IOCS is 
used compared to ABT administration.	120   
 Because of the potential consequence of returning tumor cells to a dog with HSA 
through autotransfusion, we suspect it would be prudent to include a LRF when using 
IOCS in oncologic surgery as the LRF greatly reduced the number of HSA cells.  The 
LRF failed to eliminate all tumor cells from blood that was processed through the IOCS 
system, however the need to remove all HSA cells from blood before autotransfusion is 
questioned for several reasons.  First, it has not been proven that tumor cells are shed 
and therefore collected during surgery in dogs. Tumor cells have been found in the 
operating field for several tumor types in humans.	125,137,150  The presence of tumor cells 
shed during surgery is important to determine because circulating tumor cells have 
distinct characteristics and behavior compared to tumor cells shed from the primary 
tumor in surgery.	152 HSA cells have been found in the free abdominal fluid in dogs but 
the concentration and viability of these cells shed during surgery is unknown.	15 Second, 
it is unknown if all tumor cell types are able to survive IOCS processing.  Results from 
this experiment show that whole tumor cells are present after IOCS processing but their 
viability was not tested. Third, if tumor cells survive IOCS processing and are returned 
to the patient, it is unknown if those cells are capable of forming new tumors or 
contribute to the progression of disease. Human carcinoma cells salvaged at surgery 
have been shown to be tumorigenic in immunodeficient mice, however these results may 
not apply to patients with a normal immune system or other tumor cell types.	152 
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Metastasis is an inefficient and complicated process; an estimated 0.1% of disseminated 
tumor cells are capable of forming a metastatic lesion.	154 Wang et al. estimates that in 
dogs with HSA, 1% of circulating nucleated cells are HSA cells, but their ability to form 
metastatic lesions is unknown.	155 Fourth, even if the cells survive IOCS and exhibit 
tumorigenicity, it is unknown if this affects quality of life and survival time in dogs with 
a life-limiting disease such as HSA. 
Study Limitations 
 This study has limitations, especially in regards to cell detection. The number of 
HSA cells encountered during surgery is unknown and may not have been accurately 
recreated in this study. The acceptable number of remaining tumor cells before returning 
autologous blood to a patient has not been established. While a majority of HSA cells 
can be removed with IOCS and LRF processing, the possible presence of other soluble 
mediators that permit tumor progression were not evaluated in this study. We cannot 
comment on the safety for use in clinical patients. 
   All three cell detection methods used in this experimental approach have 
limitations. In Part 1, we were able to determine the ability of flow cytometry, RT-PCR 
and cytological examination to detect 50 HSA cells/mL of culture media. Although no 
HSA cells were found in the post-LRF samples in the first trial for Part 2, we cannot 
determine if fewer than 50 HSA cells/mL of blood were present. A highly sensitive and 
specific cell detection method has been shown to detect small concentrations of cultured 
HSA cells, but this technology requires more validation and was not available to the 
investigators.	155  
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 Because of the potential consequences of ABT listed above, IOCS is a viable 
consideration for animals needing blood in the perioperative period.  The veterinary 
literature states that IOCS should be avoided in oncologic surgery to avoid iatrogenic 
tumor cell dissemination. We have shown that the LRF is capable of removing a 
majority of 300 million cultured HSA cells from dog blood. With further studies, IOCS 
with LRF has the potential to negate some of the disadvantages of ABT when used for 
dogs with HSA.  
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CHAPTER IV 
SUMMARY 
 
Hemangiosarcoma (HSA) is a biologically aggressive tumor with a poorly 
understood pathogenesis and natural history. Despite advances in veterinary oncology, 
the survival time for this tumor type has not improved in the past thirty years. The 
retrospective data from medical records of dogs undergoing surgical treatment for HSA 
showed that allogeneic blood transfusion (ABT) use was an independent predictor for 
shorter time to clinical decline. We cannot determine if ABT use is a surrogate variable 
for increasing disease severity in dogs with HSA. If the relationship between ABT and 
shorter time to clinical decline is causal, transfusion-related immunomodulation may be 
involved.  
Intraoperative cell salvage offers a practical advantage to ABT use in dogs with 
HSA that need a blood transfusion. The addition of a leukocyte reduction filter to the 
intraoperative cell salvage system may allow for this technique to be used to restore 
intravascular hemoglobin and volume support to dogs undergoing surgery to address 
bleeding intraabdominal tumors. We showed that the intraoperative cell salvage system 
and leukocyte reduction filter are able to remove a majority of HSA cells from dog 
blood.  Our results allow for future experiments to determine if this blood-conservation 
technique can be used safely in clinical settings and if intraoperative cell salvage could 
ameliorate the negative consequences of ABT use in dogs with HSA. 
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